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Single-cell droplet microfluidics for metagenomics and cancer multiomics 
 
Benjamin Demaree 
 
Abstract 
 Cellular heterogeneity is inherent to many biological systems, across both normal and 
disease states. For example, diverse ensembles of microbes in the natural environment fulfill 
distinct roles related to nutrient metabolism and gas fixation. In human cancers, genetic and 
phenotypic heterogeneity is observed among cells originating from a common oncogenic clone. 
Understanding biological heterogeneity, whether for metabolic engineering applications or the 
design of cancer therapeutics, begins at the fundamental unit of the organism: a single cell. 
Droplet microfluidics enables analyses of single cells at a biologically relevant scale through 
rapid compartmentalization and manipulation of millions of parallel reactions. In this thesis, I 
describe the development and application of single-cell genomics platforms leveraging droplet 
microfluidics to interrogate many individual genomes. These technologies enable single-cell 
metagenomics and multiomic analysis of single cancer cells, providing new insights into the 
extent of cellular heterogeneity and its implications across biology. 
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Chapter 1: Introduction 
Genomic heterogeneity within cell populations reflects the specialized functions of its 
constituents. Within metagenomic systems, diverse arrays of organisms perform 
complementary tasks and maintain a normal community structure. In the human body, cells 
sharing a common inherited genome differentiate into distinct lineages, each fulfilling vital 
physiological roles. While genomic heterogeneity is therefore an important and even necessary 
aspect of biology, genetic polymorphism can also lead to dysregulation and disease, as in 
cancer. In this thesis, I explore different facets of cellular heterogeneity through the lens of 
single-cell genomics technologies using microdroplets.  
Shifting scientific paradigms as well as key technological advances have combined to 
accelerate the recent development of single-cell sequencing technology. Early single-cell 
sequencing publications using flow cytometry to sort and isolate cells into microwells revealed 
substantial genetic mosaicism among single cancer cells5,6, and demonstrated how tumor 
evolution is reflected in single-cell DNA mutations7. Despite their small sample sizes, on the 
order of tens of cells per experiment, these studies reinforced the importance of analyzing 
genomes at the level of individual cells and motivated the development of single-cell sequencing 
technologies with higher throughputs. A series of publications in 2015, at the beginning of my 
graduate school career, were the first to demonstrate single-cell RNA sequencing at a 
biologically-relevant scale, analyzing thousands of cells simultaneously. The three microdroplet-
based technologies, dubbed Drop-Seq8, inDrop9, and Hi-SCL10, showed that individual cells 
from a section of human tissue have vastly different transcriptional profiles, depending on their 
identity and state. The introduction of these technologies marked a new era in single-cell 
genomics, where the analysis of thousands of cells is now routine. Thus, the stage was set for 
my graduate work in the rapidly expanding field of single-cell sequencing. 
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The development of microfluidic technology and decrease in sequencing costs have 
both contributed to the growth of the single-cell genomics field. The DropSeq, inDrop, and Hi-
SCL platforms, as well as the most successful commercial solution to date, produced by 10X 
Genomics, all use microdroplets to encapsulate and barcode cells. Microdroplets are small (~40 
µm), highly monodisperse water-in-oil emulsions capable of compartmentalizing cells and other 
biological reagents. The rapid and serial nature of droplet generation, producing thousands of 
droplets per second from a single microfluidic nozzle, enables biological reactions, such as 
polymerase chain reaction (PCR) or reverse transcription, to be carried out in a highly-
parallelized fashion. In addition to advances in microdroplet technology, the precipitous decline 
in sequencing cost, coinciding with the advent of next-generation sequencing (NGS) (Figure 
1.1), accelerated the expansion of single-cell sequencing. Whereas Sanger sequencing is low-
throughput and prohibitively expensive at scale, NGS can read millions of DNA fragments 
across thousands of cells in parallel, thereby pairing the throughput of droplet-based platforms 
with a complementary digital readout in the form of sequencing data. 
 
Figure 1.1: Cost per raw megabase of DNA sequencing over time. 
Adapted from NIH data11. 
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  In the chapters that follow, I describe the development and application of single-cell 
genomics platforms based on droplet microfluidic technology. 
 Chapter 2: describes SiC-seq (Single-Cell Sequencing), a technology for capturing 
whole microbial genomes at throughputs of >10,000 cells per experiment. We demonstrate a 
novel microfluidic workflow wherein single cells are compartmentalized into microgels, 
processed, and barcoded. SiC-seq data can be used to link microbial genes to host identity, 
generating a network of antibiotic resistance and virulence factor distribution for a freshwater 
community. 
 Chapter 3: details particle-templated emulsification (PTE), a method for rapidly 
emulsifying reagents into monodisperse droplets containing a hydrogel bead. Unlike 
microfluidic-based approaches to emulsification, PTE requires minimal specialized equipment 
and its processing time is independent of initial sample volume, emulsifying billions of reactions 
in a matter of seconds. We apply this method to a digital droplet PCR (ddPCR) assay, 
demonstrating that PTE-based ddPCR can accurately quantify the variant allele frequency of a 
mutation in the EGFR gene. 
 Chapter 4: describes a novel single-cell multiomic technology, dubbed DAb-seq (DNA 
and Antibody Sequencing). DAb-seq simultaneously performs targeted DNA amplification and 
protein counting in thousands of single cells, directly linking DNA mutations to corresponding 
cell immunophenotypes. Applying this technology to samples from patients with leukemia, we 
demonstrate that proteogenomic decoupling is prevalent in these cancers, both within and 
across individuals. 
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Chapter 2: SiC-Seq: Single-cell genome sequencing at ultra high-throughput with 
microfluidic droplet barcoding 
2.1. Abstract 
The application of single-cell genome sequencing to large cell populations has been 
hindered by technical challenges in isolating single cells during genome preparation. Here we 
present single-cell genomic sequencing (SiC-seq), which uses droplet microfluidics to isolate, 
fragment, and barcode the genomes of single cells, followed by Illumina sequencing of pooled 
DNA. We demonstrate ultra-high-throughput sequencing of >50,000 cells per run in a synthetic 
community of Gram-negative and Gram-positive bacteria and fungi. The sequenced genomes 
can be sorted in silico based on characteristic sequences. We use this approach to analyze the 
distributions of antibiotic-resistance genes, virulence factors, and phage sequences in microbial 
communities from an environmental sample. The ability to routinely sequence large populations 
of single cells will enable the de-convolution of genetic heterogeneity in diverse cell populations. 
2.2. Introduction 
Organisms are living expressions of their genomes and, hence, genome sequencing is a 
powerful way to study how they grow and function. Organisms are phenotypically diverse. This 
diversity is mirrored by heterogeneity at the genomic level and plays important roles in 
populations as a whole, particularly among populations of single cells. A common challenge 
when applying single-cell sequencing to heterogeneous systems is that they often contain 
massive numbers of cells: a centimeter-sized tumor can contain hundreds of millions of cancer 
cells12, while a milliliter of seawater can contain millions of microbes13. Moreover, each cell has 
a tiny quantity of DNA, making it challenging to accurately amplify and sequence single cells. 
Indeed, a long history of methods based on optical tweezers14, flow sorting15, microfluidics16,17, 
and single-cell isolation using gel matrices18–20 have been used to isolate and process hundreds 
of single cells for sequencing, but this constitutes a minute fraction of most communities. The 
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sparseness of the sampling limits the questions that can be addressed, with the majority of 
findings relating to the most abundant subpopulations. A method that could markedly increase 
the number of cells sequenced at the single-cell level would have an impact on a broad range of 
problems across biology where heterogeneity is important. 
Droplet microfluidics enables millions of independent picoliter reactions, and has recently 
been used to deep-sequence single DNA molecules21, tag nucleosomes to enable single-cell 
chromatin immunoprecipitation (ChIP)-seq22, and to profile the transcriptomes of single cells, all 
at high throughput8–10. However, sequencing the genomes of single cells presents unique 
challenges because genomic DNA must be purified from the cellular matter and processed 
through a series of enzymatic steps to prepare it for sequencing. Consequently, while droplet 
microfluidics provides the potential for sequencing of single-cell genomes at ultra-high-
throughput, no approach for accomplishing this has yet been reported. 
We describe a method for single-cell genome sequencing at ultra-high-throughput (SiC-
seq) using droplet microfluidics. In SiC-seq, we encapsulate cells in hydrogel microspheres 
(microgels) that are permeable to molecules with hydraulic diameters smaller than the pore size, 
including enzymes, detergents, and small molecules, but sterically trap large molecules such as 
genomic DNA23. This allows us to use a series of washes on encapsulated cells, to perform the 
requisite steps of cell lysis and genome processing, while maintaining compartmentalization of 
each genome. Using a combination of microgel and microfluidic processing steps, we lyse the 
cells, fragment the genomes, and attach unique barcodes to all fragments, in a workflow that 
processes >50,000 cells in a few hours. The barcoded fragments for all cells can then be pooled 
and sequenced, and the reads grouped by barcode, providing a library of single-cell genomes 
that can be subjected to additional downstream processing, including demographic 
characterization and in silico cytometry (Figure 2.1: Schematic of SiC-seq workflow.). 
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Figure 2.1: Schematic of SiC-seq workflow. 
Top: droplet workflow to generate single-cell genome-barcoded sequencing library. Bottom left: 
sequencing and generation of barcode groups representing reads from single cells. Bottom right: 
the groups of reads comprise a database of low-coverage genomes of single cells, which can be 
searched repeatedly in silico. 
 
2.3. Results 
2.3.1. SiC-seq workflow 
The principal strategy of SiC-seq is to label all DNA fragments originating from the same 
genome with a sequence identifier (barcode) unique to that cell. The resultant products are 
chimeric, comprising a barcode sequence covalently linked to a random fragment of the cell 
genome. The barcodes allow all reads belonging to a given cell to be identified through shared 
sequence. We use libraries of barcode droplets containing the barcode sequences, which we 
merge with the genome-containing droplets to be barcoded21. To prepare a barcode droplet 
library, we encapsulated into droplets, at limiting dilution, oligonucleotides comprising 15 
random bases flanked by constant sequences with PCR reagents and primers complementary 
to the constant regions of the barcodes with one side containing the Illumina P7 flow cell 
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adaptor24 (Figure 2.2a). The droplets were then thermal-cycled to amplify the barcode 
sequences via digital droplet PCR, generating ∼10 million barcode droplets in a few hours. 
 
 
Figure 2.2: Microfluidic and biochemical workflow to generate a SiC-seq library. 
(a) Generating barcode droplets by encapsulating random DNA oligos at limiting dilution and 
amplification by in-droplet PCR (SYBR-stained for visualization). (b) Cells are encapsulated at 
limiting dilution with molten agarose to generate agarose microgels each containing a single cell. 
(c) The single-cell genomes are purified through a series of bulk enzymatic and detergent lysis 
steps. (d) Microgels are re-encapsulated in droplets containing tagmentation reagents. (e) The 
droplets containing tagmented genomes are merged sequentially with PCR reagents and barcode 
droplets at a 1:1 ratio, followed by PCR to splice barcodes to genomic fragments. 
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Before the single-cell genomes can be barcoded, they must be physically isolated, 
purified, and fragmented. To accomplish this, we encapsulated single cells in agarose microgels 
using a two-stream co-flow droplet maker, which merges a cell suspension stream with a molten 
agarose stream, forming a droplet consisting of an equal volume of both streams (Figure 2.2b 
and Figure 2.3a). The droplet maker runs at ∼10 kHz, allowing us to generate ∼10 million ∼22-
μm-diameter droplets in ∼20 min in a total volume of aqueous emulsion of ∼60 μL. Hence, 
droplet generation is fast and the total volume consumed small, allowing us to load cells at a 
rate of 1:10 to minimize multi-cell encapsulation. After solidifying the agarose by cooling, the 
microgels were then transferred from oil to aqueous carrier phase to be subjected to cell lysis 
and genome purification. To lyse the cells, we incubated the microgels overnight in a mixture of 
lytic enzymes, digesting the protective microbial cell walls. We then incubated them in a mixture 
of detergents and proteases for 30 min, solubilizing lipids and digesting proteins, preserving 
only high-molecular-weight genomic DNA, which we verified by staining with SYBR green dye 
(Figure 2.2c). To fragment the genomes and attach the universal sequences to act as PCR 
handles, we re-encapsulated the gels in the Nextera reaction (Figure 2.2d and Figure 2.3b). 
Because the transposases are dimeric, the fragmented genome remained intact as a 
macromolecular complex, remaining sterically encased within the hydrogel network25 (Figure 
2.4). Nevertheless, we re-encapsulated the gels into separate droplets during fragmentation to 
ensure that there was no cross-contamination of DNA between the gels. 
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Figure 2.3: Drawings of SiC-seq microfluidic devices. 
Schematics of microfluidic devices used to: (a) generate barcode droplets and encapsulate cells 
in agarose microgels; (b) re-encapsulate gels in tagmentation reagents; (c) merge gel droplets 
with barcode droplets and PCR droplets. 
 
After the genomes were purified and fragmented, they were barcoded for sequencing. 
We used a microfluidic device that merged each microgel-containing droplet with droplets 
containing PCR reagents and a barcode droplet (Figure 2.2e and Figure 2.3c). The resulting 
droplets, which contained fragmented-genome and barcoded DNA, were collected into a PCR 
tube and thermal-cycled, splicing the barcode sequences onto the genomic fragments via 
complementarity through the PCR handles added by the transposase. At this point, the spliced 
fragments contained both the P5 and P7 Illumina sequencing adaptor required for sequencing 
10 
 
on the Illumina platforms. We removed droplets that coalesced during thermal cycling using a 
micropipette; the remaining droplets were chemically merged and their contents pooled and 
prepared for sequencing. After sequencing, the reads were filtered by quality and grouped by 
barcode, providing single-cell genomic sequence data. 
 
 
Figure 2.4: Characterizing diffusion of genomic fragments inside agarose microgels. 
(a) SYBR staining was used to monitor diffusion of genomes in microgels before and after 
tagmentation. (b) After two days at room temperature, the beads were pelleted by centrifugation 
and DNA was extracted from the beads and the supernatant and quantified using the Qubit 
dsDNA high sensitivity assay and bioanalyzer high sensitivity chip. The shift in fragment size is 
relatively minor as a result of the relatively low stoichiometric ratio of transposase to genome 
used. (c) Encapsulated genomes are reacted with a higher stoichiometric ratio of transposase to 
genome are visualized on a bioanalyzer high sensitivity chip to show fragmentation efficiency of 
the gel encapsulated genomes. 
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2.3.2. Validation of SiC-seq on an artificial microbial community 
The objective of SiC-seq is to provide single-cell genomic sequences bundled in barcode 
groups. To validate that SiC-seq generated single-cell barcode groups, we applied it to an 
artificial microbial community containing three Gram-negative bacteria, five Gram-positive 
bacteria, and two yeasts, which are typically difficult cell types to lyse. We prepared a single-cell 
library from this community using SiC-seq and sequenced it on an Illumina MiSeq, yielding ∼6 
million single-end reads of 150 bp after quality filtering. We grouped reads by barcode and 
discarded groups with <50 reads, yielding the final 48,989 barcode groups (Figure 2.5a). Each 
barcode group represented a low-coverage genome of a cell, with a sequencing depth of ∼0.1% 
to ∼1% (Figure 2.6). 
 
 
Figure 2.5: SiC-seq performance on an artificial microbial community consisting of ten different 
cell species. 
(a) Distribution of sequencing yield of each barcode group. (b) Histogram of the purity of each 
barcode group, which is defined as the fraction of reads mapping to the most mapped species for 
that group. The inset is plotted with the counts on a logarithmic scale. (c) Relative abundance 
estimates of each species using read counting, barcode counting, and two different taxonomic 
profiling programs (Kraken and MetaPhlAn 2). (d) Relative coverage of the Bacillus subtilis 
genome for all B. subtilis barcode groups, showing good uniformity. (e) Coverage histogram for 
the B. subtilis genome binned by relative coverage. 
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Figure 2.6: Lorenz curves of barcode group coverage, by species. 
The average depth and distribution of genome coverage of each barcode group plotted as a 
Lorenz curve for each species in the 10-cell control experiment. 
 
To determine whether the barcode groups indeed corresponded to single cells, we 
mapped all reads to the reference genomes of the ten species. If two microbes reside within the 
same barcode group, reads will map to two genomes. We defined a group purity score as the 
fraction of reads mapping to the most mapped reference (the ideal barcode group has a purity 
score of 1.0). The distribution of purity scores was strongly skewed to high values with the 
majority of purity scores >0.95, suggesting that most barcode groups represented single cells; 
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this result was consistent even when we took into account the different genome sizes of the ten 
species (Figure 2.5b and Figure 2.7) and when we examined purity individually for each 
species (Figure 2.8). We further examined the rare barcode groups with low (<0.8) purity scores 
and determined that the majority of those barcode groups represent rare cases where two cells 
were encapsulated into one droplet or the occasional coalescence of two single-cell-containing 
droplets (Figure 2.9). 
 
Figure 2.7: Genome size-normalized barcode group purity scores. 
Genome size-normalized purity scores of barcode groups in the 10-cell control experiment. 
Genome size-normalized purity scores are calculated using the same method using the fraction 
of the genome sequenced for each respective species rather than the raw number of reads. 
 
To determine whether the abundance of SiC-seq barcodes reflected the abundance of 
corresponding organisms in the data set, we compared abundance estimates calculated by 
short-read alignment, taxonomic profiling programs, and counting under brightfield microscopy 
(Figure 2.5c and Figure 2.10). We found that all methods were in reasonable agreement when 
reads were pooled and analyzed in bulk and when species identities were assigned to each 
barcode based on the most commonly mapped species in a group. This demonstrates that SiC-
seq enables estimation of species abundance in a microbial population consistent with accepted 
metagenomic methods. 
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Figure 2.8: Barcode group purities, by species. 
Purity scores of barcode groups separately plotted for each species in the 10-cell control 
experiment. 
 
 
 
Figure 2.9: Barcode group purity scores for second-most abundant species. 
Purity scores of the next-most abundant species in a) barcode groups of purity <80%; b) barcode 
groups of purity >80%. In barcode groups with <80% purity, the purity scores of the next-most 
abundant species tend to be high from ~20% to 50%, reflecting that those two species represent 
the majority of the reads in the barcode group, suggesting that these barcode groups represent 
double encapsulations. Barcode groups with 100% purity are not represented in the plots. Blue 
line represents cumulative barcode counts normalized to 1. 
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Figure 2.10: SiC-seq performance on an artificial 3-cell microbial community. 
Relative abundance estimates of each species are calculated using barcode counting (Barcode), 
marker gene counting without barcodes (Metaphlan), and manual counting under the microscope 
after cell encapsulation (Microscope count) and while in culture (Theoretical). 
 
Sequencing the genome of a single cell typically incurs coverage distribution bias26 due 
to uneven amplification of DNA starting from a single genome copy. To investigate coverage 
distribution bias in SiC-seq, we plotted the normalized coverage distribution for reads 
aggregated from all barcode groups for each microbe (Figure 2.5d,e and Figure 2.11). With the 
exception of coverage gaps due to the low abundance of cells of certain species within the 
standard microbial community, we observed no substantial coverage bias. This indicates that 
the sampling of each genome within a barcode group was random, so that when all groups were 
overlaid, a uniform distribution was obtained. We further inspected the distribution of reads in 
individual barcode groups and found no substantial bias. We believe that coverage bias was 
minimal because each genome was amplified in a tiny volume of ∼65 pL, which has been 
shown to curtail bias-inducing runaway of exponential amplification27. Since the sequencing 
library was composed of ∼50,000 amplified genomes, the amplification of each genome was 
limited by the tiny volume while still producing sufficient total DNA for sequencing. 
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Figure 2.11: Aggregate genomic coverage of all the barcode groups for species in the synthetic 
microbial community. 
Species at low abundance show frequent dropouts characterized by dips in the graph, but 
instances of systematic bias characterized by sharp peaks are rarely observed. 
 
2.3.3. SiC-seq data analysis with in silico cytometry 
The genomic sequences generated using SiC-seq are grouped by cell barcodes, which 
is complementary to the sequences generated from shotgun metagenomic sequencing. Existing 
computational tools are ill-suited to analyze these data because they do not exploit the single-
cell barcode information unique to SiC-seq. To address this, we utilized a sequence analysis 
pipeline in which reads are organized hierarchically as barcode groups, generating a single-cell-
reads database (SiC-Reads). To build SiC-Reads, we filtered raw sequences by quality, 
grouped them by barcode, and estimated a taxonomic classification of each group using 
phylogenetic profilers. We also estimated a purity score equal to the fraction of reads mapping 
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to the dominant taxon within the classifiable set. Additional properties of barcode groups and 
reads, such as presence of sequences corresponding to antibiotic-resistance genes, can be 
added to the database as they are discovered during analysis. 
The massive set of single-cell genomes present in SiC-Reads provides new 
opportunities for discovering associations between sequences within single cells, in a process 
we dub in silico cytometry. SiC-Reads comprises a collection of single-cell genomes that can be 
sorted in silico, analogous to what is commonly done with flow cytometry on single cells. The 
database can be sorted repeatedly to mine for correlations between different genetic sequences 
and structures. Moreover, as new associations are learned, new sorting parameters can be 
defined, enabling discoveries without having to repeat the experiment. 
2.3.4. Taxonomic distribution of antibiotic resistance in microbes 
To demonstrate in silico cytometry, we used SiC-seq to sequence a microbial community 
recovered from coastal seawater of San Francisco. We obtained ∼8 million reads of 150-bp 
length after quality filtering (representing ∼55% of raw reads), with which we generated a SiC-
Reads database. Using a phylogenetic profiler, 601,348 (6.89%) of reads were successfully 
classified into taxa representing 99.8% bacteria, 0.04% archaea, and 0.16% viruses (Figure 
2.12a). Barcode groups were assigned a taxonomic classification based on the reads they 
contained, following the rule that more than 10% of reads in a barcode group must be classified, 
and the assigned classification is the taxon with the most supporting reads. Most barcode 
groups were high purity based on the classifiable sequences (∼91% average), in accordance 
with our control sample (∼94% average) (Figure 2.12b). Using this SiC-Reads database, we 
demonstrated in silico cytometry by exploring the distribution of antibiotic resistance, virulence 
factors, and phage sequences in the microbial community. 
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Figure 2.12: Analysis of the marine microbial community used to demonstrate in silico 
cytometry. 
(a) Taxonomic abundance of the SiC-Reads database by barcode groups; (b) Distribution of purity 
of barcode groups in the database at the genus level. 
 
Antibiotic resistance has become increasingly common and represents a considerable 
threat to global human health28. While antibiotic-resistance genes can be identified in most 
environments by short-read sequencing, scant information on how they are distributed among 
taxa is available, because obtaining this information usually requires testing or whole genome 
sequencing of single species; however, culture conditions for most species have not been 
identified, precluding such analyses. 
To determine the distribution of antibiotic-resistance genes among taxa in our data set, 
we searched our SiC-Reads database for known antibiotic-resistance genes, finding 1,081 
(0.012% of reads), representing 108 (0.30%) barcode groups. The taxonomic distribution of 
antibiotic-resistance genes in our database had a clear structure, although it did not correlate 
with what is known from genomes in public databases (Figure 2.14a and Figure 2.13a). This is 
unsurprising as differences are expected in the natural coastline environment compared to the 
environment of isolated and sequenced strains. The most abundant taxa associated with 
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antibiotic resistance were not the most abundant community members overall, suggesting that 
in this community, certain taxa tend to associate more with antibiotic-resistance genes. 
 
Figure 2.13: Simulation of sequencing data from marine strains. 
Reference data obtained by simulating reads from genomic sequences of isolated strains for 
comparison against data in the marine microbial community. (a) Antibiotic resistance network for 
whole genome sequenced strains in public databases; (b) Virulence factor ratios calculated for 
publically available strains. 
 
2.3.5. Association of virulence factors with host bacteria 
Virulence factors, like antibiotic-resistance genes, are important genetic factors in 
determining the threat that specific microbes pose to human health. Many opportunistic 
pathogens reside in natural communities in the environment and cause outbreaks when 
transmitted to a suitable host29. Monitoring and detecting potentially pathogenic microbes is 
important for public health. Like antibiotic-resistance genes, traditional methods can detect the 
presence of these genes but not their taxonomic distribution. 
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Figure 2.14: Application of SiC-seq to a marine community recovered from the San Francisco 
coastline. 
(a) Distribution of antibiotic-resistance genes according to genus of host microbe. The more 
opaque the lines connecting the circles, the greater the number of interactions detected in the 
database. (b) Relative abundance of virulence factors in each genus detected in the community. 
(c) Relative potential for transduction between bacterial taxa, determined by the relative number 
of common phage sequences detected in their respective genomes, plotted as a heat map. 
 
To examine the taxonomic distribution of virulence factors in our data set, we searched 
our coastal microbial community database for known virulence factor genes, yielding matches in 
1,949 (0.022%) reads in 101 (0.28%) barcode groups, consisting of 29 prevalent virulence 
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factors distributed among 13 microbial genera. The abundance of each taxa where virulence 
factors were found did not reflect their abundance in the total population, suggesting that certain 
genera tend to carry more virulence factors than others. To quantify this, we calculated the 
virulence factor ratio, the ratio between the number of barcode groups containing virulence 
factors and the total number of barcodes in the community for that species, and normalized the 
results to the highest virulence factor ratio for comparison (Figure 2.14b). Haemophilus and 
Escherichia stand out among all species; both are known opportunistic human pathogens.  
Comparing the virulence factor ratios of the San Francisco coastline community with 
ones calculated for publicly available whole genomes and downsampled to match our per-cell 
read depth (Figure 2.13b), we found that the ratios were higher for the public genomes, an 
expected result given that isolated and sequenced genomes are biased toward pathogenic 
strains. 
2.3.6. Determining transduction potential between bacteria 
Many virulent bacterial strains are thought to arise from horizontal gene transfer aided by 
cross-infection of bacteriophages. Phages can modify the genomes of their hosts, leaving a 
copy of their own genome behind or transporting fragments of one species to another in a 
process known as transduction30,31. Characterizing the distribution of these mobile elements is 
challenging in an ecological context because confident identification of foreign genomic 
fragments within a specific host requires sequencing large numbers of cultures of single species 
or single cells. Nevertheless, this information is valuable for understanding how bacteria transfer 
genetic material in general, and how virulent new strains may emerge through this mechanism. 
To explore transduction in the microbial community, we searched the SiC-Reads 
database of the San Francisco coastal community for barcode groups containing phage 
sequences. A phage sequence found in a bacterial genome is evidence of infection, an 
association that is normally extremely difficult to make for uncultivable microbes and their likely 
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uncultivable infecting phages. We found matches in 6,805 (0.078%) reads representing 260 
(0.72%) barcode groups and 106 phage genomes. Since transduction can occur between two 
host cells that can be infected by the same phage, the potential for transduction depends on the 
likelihood of phages infecting both hosts. To visualize this, we plotted the normalized sum of the 
number of times we detected the sequences matching to the same phage in two bacterial taxa, 
normalized by the number of barcode groups in those taxa (Figure 2.14c). According to this 
analysis, Delftia and Neisseria, which are the most closely related out of the taxa in our 
analysis, had the highest potential for transduction. The dearth of representative phage 
genomes in databases and the limited sequence information per barcode group limited the 
accuracy of this approach. Therefore, higher coverage of the genomes and better phage 
genome databases are required to definitively identify the phages that are found in the 
database. Nevertheless, SiC-seq's ability to detect these sequences and correlate them within 
single genomes can provide a useful approach to study phage–host interactions. 
2.4. Discussion 
SiC-seq generates a metagenomic database grouped by single-cell genomes amenable 
to repeated mining by in silico cytometry, for rapid hypothesis generation and testing. We 
demonstrated its use in measuring the distributions of antibiotic-resistance genes, virulence 
factors, and transduction potential in microbial communities. The ability of SiC-seq to sequence 
all cells in a sample without the need to culture them should help us to characterize the 
microbial dark matter. 
The barcoded nature of SiC-seq data necessitates additional quality control measures 
for the data, in addition to the quality control measures used in standard sequencing. First, the 
barcode reads themselves must be of high quality, thus any reads containing low-quality 
barcode sequences are eliminated, regardless of the quality of the genomic sequences. 
Second, barcode groups must be quality-controlled to remove small barcode groups, which are 
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the result of mutations in the barcode sequences and background contamination of free DNA. 
These quality control measures together result in a typical yield of ∼55% of raw reads 
contributing to the SiC-Reads database. Improvements in yield can be made by, for example, 
computationally identifying reads with mutated barcodes and 'correcting' their sequence, but we 
have found only modest improvements in yields using this method alone21. 
The taxonomic classification of microbes remains an integral part of studying community 
dynamics, from ecosystems on Earth to those residing in and on our bodies32,33. However, the 
taxonomic classification of short reads is error prone, due to the diversity of microbes in most 
communities and the high degree of horizontal gene transfer that mixes genomic elements in 
unpredictable ways. SiC-seq improves upon traditional metagenomics sequencing in addressing 
this challenge because taxonomic identification can be made on the basis of hundreds of reads 
within a barcode group. Advanced strategies can be applied to infer the taxonomy of a barcode 
group, including Bayesian probabilistic ones based on classification of each read in the group, 
or ones weighted toward specific taxonomic markers. Even with this improvement, accurate 
classification is difficult because the vast majority of sequences remain unclassifiable and the 
classification of sequences are biased toward well-sequenced taxa in the databases. As 
genome coverage improves in future iterations of SiC-seq, taxonomic classification of barcode 
groups should become more confident and precise, potentially arriving at classifications down to 
the strain under certain circumstances. It is worth noting that taxonomic classification with SiC-
seq is also subject to the fundamental limitations of reference-based classification paradigms, 
where the classification is only as accurate as the match between the sample and the 
references. Hence, like traditional methods, SiC-seq phylogenetic profiling will become more 
reliable and complete with the expanding database of reference genomes. 
The degree of genome coverage affects the usefulness of single-cell data, including the 
ability to generate assemblies or identify characteristic sequences for in silico cytometry. A 
limitation of SiC-seq is that, while the number of cells sequenced far exceeds currently 
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described methods, the coverage per cell is substantially lower. Therefore, dropouts in coverage 
and false negatives can be expected in in silico cytometry analysis. For abundant organisms 
with a random distribution of coverage in each barcode group, the system is robust to dropouts 
because results are averaged over many barcode groups. For example, approximately 7,000 
Alteromonas barcode groups were taken into account to determine the antibiotic-resistance 
profile for Alteromonas bacteria. However, for less abundant species, such as Haemophilus, 
more dropouts can be expected because there may not be enough total sequence information 
to detect a specific genetic factor. For this reason, the analysis of SiC-Read databases should 
be limited to relative comparisons of species within the database, and the abundance of target 
genes within subpopulations should be normalized to the number of barcode groups in the 
subpopulation. It is worth noting that the dropout phenomenon is not unique to SiC-seq data, but 
applies to all metagenomic sequencing data where the subpopulation to be analyzed represents 
a very small fraction of the whole. 
Although coverage can be increased by sequencing more reads, the coverage per cell 
per barcode group will be <100%. This is because the method begins with a single genome 
copy without amplification and losses incurred during enzymatic and microfluidic processing are 
irrevocable, thus limiting the maximum coverage attainable. In future iterations of SiC-seq, 
coverage may be increased by amplifying genomes before processing, for example, with 
multiple displacement amplification in droplets18. Additionally, different strategies for barcoding 
genomes may yield higher coverage, such as recently described combinatorial indexing via 
transposase libraries25, which should be applicable to single-cell genomes encapsulated in 
microgels. 
The de novo assembly of whole genomes from metagenomics sequences is a common 
goal in the field of metagenomics. Mate-paired sequencing can be used to bridge contigs in a 
metagenomics sequencing data set and potentially assemble whole genomes given sufficient 
coverage34. Though powerful, the method is limited by the required micrograms of starting DNA, 
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which can be difficult to obtain from microbial ecosystems. Furthermore, many mate-paired 
reads are required to assemble a whole genome, since each mate-pair bridges only two contigs. 
SiC-seq data improve on mate-paired sequencing in this respect by requiring minimal amounts 
of sample as well as enabling the bridging of multiple contigs per barcode group. Consequently, 
SiC-seq should allow generation of draft genomes from shotgun metagenomic data with far less 
DNA input and sequencing effort. 
While we focused on microbial communities, SiC-seq is also applicable to populations of 
mammalian cells, where it can have a more direct impact on human health. The grouped reads 
provided by SiC-seq should afford the information required to determine copy-number variations 
within the genome, which is relevant to cancer35. The enormous size of mammalian genomes, 
however, limits the number of cells that can be sequenced for a target level of coverage. 
Nevertheless, as the cost of sequencing continues to decrease, more cells can be sequenced to 
greater depth, creating opportunities for characterizing mammalian tissues, cell by cell. 
The SiC-seq method is a means to isolate and barcode large DNA molecules, 
irrespective of the entity from which they originate. While we have focused on cells, similar 
approaches can be applied to any entities whose genomes can be trapped and processed 
within the gel matrix. SiC-seq's ability to build and mine large databases of genomes grouped 
by single cells should contribute to the characterization of heterogeneity across biology. 
2.5. Methods 
2.5.1. Microfluidic devices 
The microfluidic devices are fabricated by pouring poly(dimethylsiloxane) (Dow Corning, 
Sylgard 184) over a negative photoresist (MicroChem, catalog no. SU-8 3025) patterned on a 
silicon wafer (University Wafer) using UV photolithography. The PDMS devices are cured in an 
oven for 1 h, extracted with a metal scalpel, and punched with a 0.75-mm biopsy core (World 
Precision Instruments, catalog no. 504529) to create inlets and outlets. Devices are bonded to a 
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glass slide using an oxygen plasma cleaner (Harrick Plasma), and the channels treated with 
Aquapel (PPG Industries) and baked at 80 °C for 10 min to render them hydrophobic. 
2.5.2. Barcode emulsions 
Barcode emulsions are prepared through a digital PCR process wherein barcode 
oligonucleotides are amplified as single molecules in droplets containing PCR reagents. 
Barcode oligonucleotides 
(GCAGCTGGCGTAATAGCGAGTACAATCTGCTCTGATGCCGCATAG 
NNNNNNNNNNNNNNNTAAGCCAGCCCCGACACT) (IDT) at 0.01 pM concentration are added 
to a PCR reaction mix containing 1× NEB Phusion Hot Start Flex Master Mix (NEB, catalog no. 
M0536L), 2% (w/v) Tween 20 (Sigma-Aldrich, catalog no. P9416), 5% (w/v) PEG-6000 (Santa 
Cruz Biotechnology, catalog no. sc-302016), and 400 nM primers FL128 
(CTGTCTCTTATACACATCTCCGAGCCCACGAGACGTGTCGGGGCTGGCTTA) and FL129 
(CAAGCAGAAGACGGCATACGAGATCAGCTGGCGTAATAGCG, contains P7 adaptor 
sequence) (IDT). The PCR mixture and HFE-7500 fluorinated oil (3M) with 2% (w/w) PEG-
PFPE amphiphilic block copolymer surfactant (008-Fluoro-surfactant, Ran Technologies) are 
loaded into separate 1-mL syringes (BD) and injected at 300 and 500 μL/h, respectively, into a 
flow-focusing droplet maker using syringe pumps (New Era, catalog no. NE-501), controlled with 
a custom Python script (https://github.com/AbateLab/Pump-Control-Program). The emulsion is 
collected in PCR tubes, and the oil underneath the emulsion removed by pipette and replaced 
with FC-40 fluorinated oil (Sigma-Aldrich, catalog no. 51142-49-5) with 5% (w/w) PEG-PFPE 
amphiphilic block copolymer surfactant for improved thermal stability. The emulsion is thermal 
cycled (Bio-Rad, T100) with the following program: 98 °C for 3 min, followed by 40 cycles with 2 
°C per second ramp rates of 98 °C for 10s, 62 °C for 20s, and 72 °C for 20s, followed by a hold 
at 12 °C. Fluorescent DNA staining using 10× SYBR Green I (Thermo Fisher Scientific) in HFE-
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7500 oil is used to quantify barcode encapsulation rate under a fluorescent microscope (Life 
Technologies, catalog no. AMAFD1000). 
2.5.3. Water sample collection and filtering 
To obtain a natural sample of a microbial community, we collected marine water from 
Ocean Beach in West San Francisco, California, USA (37°44′55.6″N 122°30′33.6″W). 
Approximately 2 liters of water is obtained by submerging two 1,000-mL glass bottles below the 
water surface ∼20 m from the shoreline. Samples are placed on ice during transport to the 
laboratory. 100 mL of the sample is passed through a 40-μm cell strainer (Corning, product no. 
352340) to remove large debris, including sand. The sample is loaded into a 0.45 μm vacuum 
filter (Millipore, catalog no. SCHVU01RE); this filtering step separates microbes, which are 
captured on the membrane, and viruses, which are discarded in the filtrate. The membrane is 
extracted from the apparatus using a scalpel and inserted into a 15-mL centrifuge tube, to which 
5 mL of PBS is added. The tube is vortexed at high speed for ∼2 min to free the bacterial cells 
from the membrane. Finally, the cell solution is loaded into a 10-mL syringe and passed through 
a 5-μm syringe filter (Millipore, catalog no. SLSV025LS) to remove remaining large particulate. 
The marine cells are counted using the same protocol as the liquid cultures. 
2.5.4. Cell encapsulation in agarose microgels 
To prepare the artificial community for processing through the SiC-seq workflow, the 
frozen stock of cells (Zymo Research, catalog no. D6300) is thawed gently in a room-
temperature water bath. Cell concentration is determined by manual cell counting under a 
microscope, and diluted to an appropriate concentration for single-cell encapsulation. The 
calculated volume of cell solution is transferred to a 1.5-mL centrifuge tube (Fisher Scientific) 
and washed twice in 1 mL PBS. The cells are re-suspended in a 1-mL solution of PBS 
containing 17% OptiPrep Density Gradient Medium (Sigma-Aldrich), 0.1 mg/mL BSA (Sigma-
Aldrich, catalog no. A9418), and 1% (v/v) Pluronic F-68 (Life Technologies). The cell solution is 
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loaded into a 1-mL syringe and placed on a syringe pump (New Era, catalog no. NE-501). 1 mL 
of a 3% solution of low gelling temperature agarose (Sigma-Aldrich, catalog no. A9414) and TE 
buffer (Teknova, catalog no. T0225) is prepared in a 1.5-mL centrifuge tube and heated on a 
block at 90 °C for approximately 10 min to completely dissolve the agarose powder. The hot 
agarose is transferred to a 1 mL syringe and placed on a syringe pump. To keep the agarose 
molten during the microfluidic experiment, a personal space heater is positioned ∼5 cm from the 
agarose syringe and set to run continuously at high heat. HFE-7500 fluorinated oil with 2% 
(w/w) de-protonated Krytox surfactant (DuPont, catalog no. 157FSH) is loaded into a 3-mL 
syringe. The cell solution, molten agarose, and oil are injected into the co-flow droplet maker at 
flow rates of 200, 200, and 400 μL/h, respectively, to form the 1.5% agarose microgels. 
Approximately 500 μL of droplets are collected in a 15-mL centrifuge tube on ice and incubated 
for 30 min at 4 °C to ensure complete solidification of the microgels. 
2.5.5. Resuspending microgels in aqueous buffer 
The droplets are centrifuged at 300g for 1 min to maximize separation of the emulsions 
from the oil. The oil layer is extracted from the tube using a 5-mL syringe and discarded. 
Emulsions are broken using 2 mL of a 10% (v/v) solution of perfluoro-octanol (Sigma-Aldrich, 
catalog no. 370533) in HFE-7500; the emulsions are then mixed by pipetting and centrifuged at 
300g for 1 min. The oil is removed from the tube using a syringe, and the droplet breaking step 
is repeated. Following droplet breaking, 2 mL of hexane containing 1% (v/v) Span 80 (Sigma-
Aldrich) is added to the microgels to dissolve any remaining oil, and this solution is mixed and 
centrifuged at 300g for 1 min. The hexane supernatant is removed from the tube and the 
hexane addition step is repeated. Finally, the microgels are washed three times in 10 mL of 
aqueous solution TE buffer containing 0.1% (v/v) Triton X-100 nonionic surfactant (Sigma-
Aldrich). The microgels are centrifuged at 1,000g for 2 min and the supernatant aspirated 
between washes. The washed microgels are stored in 5 mL TE buffer at 4 °C before cell lysis. 
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2.5.6. Cell lysis in microgels 
To lyse the cells in the microgels, the particles are submerged in a solution of 2 mL TE 
buffer solution containing 10 mM DTT (Teknova), 2.5 mM EDTA (Teknova), and 10 mM NaCl 
(Sigma-Aldrich). The following quantities of lytic enzymes are also included: 4 U zymolyase 
(Zymo Research), 10 U lysostaphin (Sigma-Aldrich, catalog no. L7386), 100 U mutanolysin 
(Sigma-Aldrich, catalog no. M9901), and 40 mg lysozyme (MP Biomedicals, catalog no. 
195303). Cell lysis proceeds overnight in a shaking incubator at 37 °C. The turbid lysate mixture 
is centrifuged at 1,000g for 1 min, the supernatant removed, and 3 mL of a solution containing 
0.5% (w/v) lithium dodecyl sulfate (Sigma-Aldrich) and 10 mM EDTA in TE buffer is added, 
along with 4 U of Proteinase K (NEB) to solubilize cell debris and digest cellular proteins. The 
solution is incubated at 50 °C on a heating block for 30 min. Following lysis, the microgels are 
thoroughly washed to ensure complete removal of detergents and other chemical species, 
which may inhibit downstream molecular biology reactions. The following washes occur in 10-
mL volumes with centrifugation magnitudes of 1,000g between additions of wash solutions: one 
wash with 2% (v/v) Tween 20 in water; one wash in 100% ethanol (Koptec) to denature any 
remaining Proteinase K; and five washes with 0.02% (v/v) Tween 20 in water. 
2.5.7. Tagmentation of genomic DNA in microgels 
Using reagents from a Nextera DNA Library Prep Kit (Illumina, catalog no. FC-121-
1030), the washed and lysed gels containing high-molecular-weight genomic DNA are 
simultaneously fragmented and tagged with a common adaptor sequence. Microgels are re-
encapsulated into droplets to minimize cross-contamination during the tagmentation step. A 
solution of 192 μL DI water, 200 μL tagmentation buffer, and 8 μL Nextera enzyme is prepared 
and loaded into a 1-mL syringe. Microgels and the tagmentation solution are injected into the re-
encapsulation device. The re-encapsulated microgels are incubated in a 1.5-mL tube on a 
heating block at 50 °C for 1 h. 
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2.5.8. Microfluidic barcoding of encapsulated cells 
Tagmented microgel droplets, barcode droplets, and 500 μL of PCR solution containing 
1× Invitrogen Platinum Multiplex PCR Master Mix (Thermo Fisher Scientific, catalog no. 
4464268), 400 nM primers FL127 
(AATGATACGGCGACCACCGAGATCTACACTCGTCGGCAGCGTC, contains P5 adaptor 
sequence) and FL129 (CAAGCAGAAGACGGCATACGAGATCAGCTGGCGTAATAGCG), 50× 
dilution of NT buffer from the Nextera XT Kit (0.2% SDS) (Illumina, catalog no. FC-131-1024), 
1% (w/v) Tween 20, 1% (w/v) PEG-6000, 2.5 U/μL Bst 2.0 WarmStart DNA Polymerase (NEB, 
catalog no. M0538S) are each loaded into a 1-mL syringe and injected into the sequential 
merger device. HFE-7500 fluorinated oil with 2% (w/w) 008-Fluorosurfactant is used as the 
continuous phase of the emulsion. Merger of the barcode and gel droplet emulsions is achieved 
using an electrode connected to a cold cathode fluorescent inverter and DC power supply 
(Mastech). A voltage of 2.0 V at the power supply produces a ∼2 kV AC potential at the 
electrode, which causes touching droplets to merge. The emulsion is collected in a 0.5-mL thin-
walled PCR tube (Applied Biosciences), and the HFE-7500 replaced with FC-40 with 5% (w/w) 
008-Fluorosurfactant before thermal cycling with the following protocol: 65 °C for 5 min, 95 °C 
for 2 min, then 30 cycles at 2 °C/s ramp rates of 95 °C for 15s, 60 °C for 1 min, 72 °C for 1 min, 
and then 72 °C for 5 min with optional 12 °C overnight hold. After thermal cycling, large 
(coalesced) droplets are removed using a micropipette, and the emulsion is broken by addition 
of 20 μL of perfluoro-octanol and brief centrifugation in a micro-centrifuge. The upper aqueous 
phase is collected and the DNA library is purified using a Zymo DNA Clean & Concentrator-5 kit 
(Zymo Research). The library is size-selected for DNA fragments in the 200- to 600-bp range 
using Agencourt AMPure XP beads (Beckman Coulter), quantified with a Bioanalyzer 2100 
instrument and High Sensitivity DNA chip (Agilent), and sequenced on an Illumina MiSeq using 
a custom index primer (GCCCACGAGACGTGTCGGGGCTGGCTTA). 
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2.5.9. Generating the SiC-Reads database 
Raw reads from the MiSeq-generated FASTQ files are filtered by quality and grouped by 
barcode sequence using the Python script barcodeCleanup.py. A given read is discarded if 
more than 20% of its bases have a Q-score less than Q20, and all reads associated with a 
barcode containing less than 50 reads are discarded. This step ensures that all barcode groups, 
representing single cells, contain a sufficient number of high-quality reads. The resulting reads 
are exported to a table in a SQLite database with fields containing the barcode sequence, 
barcode group size, a unique read ID number, and read sequence. When the reference 
genomes are known, as in the case of the synthetic cell population experiment, the reads are 
aligned using bowtie2 v2.2.9 with default settings and the SQLite table is updated with relevant 
alignment information for each read. For environmental samples, the reads are classified by 
taxonomy using Kraken v0.10.5 with “–quick–min-hits 2” options set, and the output is exported 
to the SQLite database. Where noted, an alternative taxonomic classifier, metaphlan2 v2.6.0, 
was used with the default marker information file and taxonomic level set to “species only.” 
krakenAnalysis.py assigns taxonomic identities from the Kraken database to barcode groups by 
a majority rule, in which a barcode group is classified according to the most common taxonomic 
label among its classifiable reads. Barcode group purity is calculated from reference alignment 
data or phylogenetic labels using the script purity.py. 
2.5.10. In silico cytometry 
Reads from the SiC-Reads database are aligned, using bowtie2 v2.2.9 with –very-
sensitive and –end-to-end settings to reference sequences of interest. The antibiotic resistance 
database was obtained from36, virulence factor database obtained from core virulence factor 
genes at the virulence factor database (VFDB)37, and the phage sequence database obtained 
from Phage genome database accessed on May 2016 at 
http://www.ebi.ac.uk/genomes/phage.html. Mapping reads are then filtered for MapQ > 2 in 
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order to remove ambiguously mapping reads. Barcode groups containing reads that map to the 
databases are annotated as containing the target sequence and are exported for further 
analysis if they are taxonomically classified with purity >0.8. To generate the heatmap for 
transduction potential, all reads associated with a phage and a Kraken-classified barcode group 
were extracted and grouped according to phage type. Duplicate and near-duplicate reads were 
removed. The heatmap intensities were calculated as follows: for a given pair of bacterial hosts, 
the total number of host-phage-host connections in the database were counted. To normalize 
the data by host abundance, this number was divided by the total number of barcode groups 
associated with the two hosts. 
2.5.11. Calculating the virulence factor ratios 
The virulence factor ratios calculations in Figure 2.14b of the main text was reproduced 
using reference genomes for the genera shown in the figure. The complete genomes of all 
species associated with these 12 genera were downloaded from the RefSeq database using the 
Perl script ncbiDownloader.pl. Genomes were pooled into FASTA files labeled by genus. From 
these reference files, a Python script (bargroupGenerator.py) generated simulated barcode 
groups of 200 reads per group, with each single-end read 150-bp long. The number of 
simulated barcode groups generated for a given genus was equal to the number of barcode 
groups identified for this genus in the San Francisco Coast water sample. The simulated 
barcode group reads were then aligned to the original virulence factor database using bowtie2 
v2.2.9 in 'local' alignment mode with default sensitivity settings. Unaligned sequences were 
removed using Samtools v1.3.1 (samtools view -b -F). 
2.5.12. Generating the antibiotic-resistance network with reference genomes 
An antibiotic resistance graph in was generated using references for the six genomes 
most commonly associated with antibiotic resistance in the SiC-Reads database of the San 
Francisco Coast water microbial community. The following genomes (with accession numbers) 
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were downloaded from the NCBI RefSeq repository: Alteromonas macleodii ATCC 27126 
(CP003841.1), Bacillus subtilis subsp. spizizenii strain NRS 231 (CP010434.1), Delftia 
acidovorans SPH-1 (CP000884.1), Enterobacter cloacae subsp. cloacae ATCC 13047 
(CP001918.1), Neisseria meningitidis MC58 (AE002098.2), Propionibacterium acnes 
KPA171202 (AE017283.1). These genomes were combined into a single FASTA file and 
passed to a short-read simulator, wgsim v0.3.2, which generated 10 million single-end reads of 
70 bp each with a base error rate of 0. These reads were aligned to the antibiotic-resistance 
gene reference using bowtie2 in 'local' mode with default sensitivity settings. All unaligned 
sequences were removed using Samtools (samtools view -b -F). The aligned sequences in 
SAM format were imported into Cytoscape v3.4.0, and the network shown was generated using 
the reference genus and antibiotic-resistance genes as the network targets and sources, 
respectively. The darkness of the graph's edges scale linearly with the total number of 
connections in the data, where darker lines have a greater number of associations. 
2.5.13. Characterizing diffusion of genomic DNA fragments in agarose microgels 
A microgel sample containing encapsulated, lysed bacteria was stained with SYBR 
Green I and observed under a fluorescent microscope before and after tagmentation at various 
time points. In another experiment, the concentration of DNA in the supernatant and contents of 
the gels was measured in a sample incubated at room temperature. After 2 d at room 
temperature, the beads were pelleted by centrifugation; the DNA was extracted from the beads 
and from the supernatant, using a DNA gel extraction kit and a DNA clean-up and concentrator 
kit (Zymo research D4001T); the extracted DNA was quantified using the Qubit dsDNA high 
sensitivity assay and Bioanalyzer High Sensitivity dsDNA chip. As an additional experiment, 
microgels were incubated at 55 °C with and without tagmentation enzyme to demonstrate the 
corresponding change in genomic DNA fragment size distribution before and after tagmentation. 
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2.5.14. Cell culture and counting 
To generate an additional artificial community with which to validate the SiC-seq 
workflow, liquid cultures of Staphylococcus epidermidis, Saccharomyces cerevisiae (strain 
S288c), and Bacillus subtilis (strain 168) were grown overnight in a shaking incubator. The 
following culture conditions were used: Staphylococcus epidermidis and Bacillus subtilis were 
grown in 3-mL LB broth at 37 °C; Saccharomyces cerevisiae was grown in 3 mL YPD broth at 
30 °C. Cell concentration is determined by manually counting serial dilutions of the liquid culture 
on plastic slides (Thermo Fisher Scientific, catalog no. C10228) using a microscope. The 
cultures were kept at 4 °C before being used in the microfluidic experiment.  
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Chapter 3: Direct quantification of EGFR variant allele frequency in cell-free DNA using a 
microfluidic-free digital droplet PCR assay 
3.1. Abstract 
Analysis of liquid biopsy samples is a promising diagnostic intervention for noninvasive 
detection and monitoring of cancer genotypes. However, current methods used to assess 
mutation status are either costly, in the case of next-generation sequencing-based assays, or 
lacking in sensitivity, in the case of bulk quantitative PCR measurements. Digital droplet PCR 
(ddPCR) is at once a sensitive and low-cost method for detecting rare cancer mutations and 
measuring their variant allele frequency. In this chapter, we describe a method for conducting 
ddPCR assays without microfluidics in a process called “particle-templated emulsification” 
(PTE). Using hydrogel particles and a standard benchtop vortexer to rapidly emulsify large 
volumes, the method forgoes the specialized instrumentation required for conventional ddPCR 
assays and is capable of high experimental throughput. To assess the quantitative performance 
of the method, we apply PTE ddPCR to analysis of variant allele frequency in EGFR, a 
commonly mutated gene in lung adenocarcinomas. 
3.2. Introduction 
Lung cancer has the highest mortality rate of all cancers, accounting for 19.4% of all 
cancer-related deaths worldwide38,39. Lung adenocarcinoma (ADC) in non-small-cell lung cancer 
(NSCLC) accounts for most primary lung cancers38. Within the ADC varieties, mutation status in 
the epidermal growth factor receptor (EGFR) gene is a strong predictor of therapeutic response 
and metastatic stage40. However, invasive tissue biopsies are difficult and impractical for routine 
clinical management and detection of new cases of cancer. Cell-free DNA (cfDNA), DNA which 
is released into plasma from tumor tissues or circulating tumor cells, harbors the cancer 
mutations and is accessible using a simple liquid biopsy. A technical challenge associated with 
cfDNA-based diagnostics, however, is the high background of host DNA. The variant allele 
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frequency (VAF) of the cancer allele compared to wildtype can be as low as 0.1%, necessitating 
sensitive assays41. 
Next-generation sequencing offers the highest sensitivity of existing methods but is 
costly and has a longer turnaround time, delaying clinical action42. Quantitative PCR is the most 
widely used clinical diagnostic method for cfDNA, but has a high limit of detection (2–5% 
minimum variant allele frequency for the commercial Roche Cobas kit) and does not allow for 
direct determination of allelic frequency of cancer mutations43. Digital droplet PCR has higher 
sensitivity and can directly quantify allelic frequency of cancer mutations without need of a 
standard curve because it provides an absolute count of all variants41. However, existing digital 
droplet PCR (ddPCR) platforms rely on proprietary droplet analysis hardware, which is 
expensive. Furthermore, microfluidic devices are required to process the sample into droplets, 
which are prone to clogging, limit the number of samples that can be analyzed, and require 
transfer of reagents between tubes and microfluidic components, increasing the chances for 
sample contamination. A digital droplet assay without complex hardware and sample processing 
bottlenecks would enable rapid and quantitative profiling of cfDNA for making clinical decisions 
related to lung cancers. 
We describe a method to detect and quantify the variant allele frequency of an EGFR 
mutation using a digital droplet PCR assay that uses no microfluidics or specialized equipment. 
The approach is based on particle-templated emulsification (PTE) which partitions reactions into 
monodispersed droplets via simple vortexing of the sample container. Reagents do not need to 
be transferred between components, and the approach can emulsify large numbers of samples 
in parallel stored in microplate arrays. Moreover, the time to emulsify the sample is independent 
of the sample volume and takes ~ 30 s. As we demonstrate, PTE droplets can be used to detect 
and quantify EGFR mutants in a sample. Moreover, by multiplexing the reaction and using two 
hydrolysis probes labeled with dyes of different colors, we can identify wildtype or mutant alleles 
in droplets and quantify variant allele frequency (down to 1%) with fluorescence imaging data. 
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Our method should enable more sensitive ddPCR by being compatible with high-volume clinical 
sample processing and by eliminating the need for specialized droplet analyzers. 
3.3. Discussion 
In ddPCR, a sample containing DNA to be quantified is encapsulated into millions of 
picoliter-volume droplets, such that most partitions are devoid of the target and a small fraction 
contain it. At such limiting dilution, droplet occupancy by the targets follows a Poisson 
distribution, allowing the measured fraction of positive droplets to be converted into a 
concentration measurement. Digital quantification affords significant advantages over real time 
measurement of amplification rates as in qPCR, because the sensitivity increases as the 
number of partitions is increased, and there is no need for a standard curve by which to 
interpolate starting concentration from amplification kinetics, as in qPCR. Digital droplet PCR 
thus affords higher sensitivity and absolute molecule counts, making it valuable for applications 
requiring robust and accurate quantitation of targets, such as in the clinic. Consequently, 
ddPCR has been used to measure variant allele frequencies of DNA samples harboring rare 
mutations, such as in cell-free DNA (cfDNA) from plasma of patients with cancer. The cfDNA 
originating from circulating tumor cells and tissue contains mutations which can provide 
information about the metastatic potential and therapeutic susceptibility of a given condition40,41. 
In lung adenocarcinomas, mutations in the EGFR gene are common but difficult to 
detect in a liquid biopsy due to the high background of DNA from other host cells without the 
mutation44. Here, we describe a digital PCR method employing particle-templated emulsification 
(PTE) for quantification of a specific EGFR mutation without the use of complex microfluidic 
devices or well plates. Much like conventional digital PCR in droplets, the water-in-oil emulsions 
serve as reaction partitions and allow digital amplification of target template. However, rather 
than using a microfluidic device to generate the droplets, PTE uses polyacrylamide microgels to 
engulf the sample into the partitions. A powerful advantage of PTE is that all of the 
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emulsification occurs in the original sample tube; thus, the sample need not be transferred 
between reservoirs, tubing, and microchannels, as in microfluidic devices, making the approach 
simple and robust to contamination. Moreover, while in microfluidic emulsification the time to 
process the sample scales with the sample volume, with PTE emulsification takes ~ 30 s, for 
samples ranging from tens of microliters to milliliters. These properties make the approach 
scalable in the number of samples processed and in the volume processed per sample. 
 
 
Figure 3.1: Digital PCR workflow using particle-templated emulsification. 
(a) Polyacrylamide beads are soaked in PCR mix, allowing amplification components to diffuse 
throughout the bead volume. (b) Beads are emulsified using a simple laboratory vortexer which 
creates the necessary hydrodynamic shear for efficient partitioning. (c) The contents of the 
emulsions are PCR-amplified in a conventional thermal cycler. In partitions containing the target 
nucleic acid sequence, the polymerase cleaves the hydrolysis probes and emits a fluorescent 
signal. (d) Droplets are imaged under a microscope to capture fluorescence intensity values within 
each droplet. (e) Populations of droplets are analyzed using image processing tools. Counts of 
mutant and wildtype droplets are used to calculate the variant allele frequency. 
 
 
The workflow begins by adding the microgels to the sample, which contains the target 
DNA template and amplification reagents. Depending on the porosity of the hydrogel particles, 
some components of the sample, such as small molecules, will diffuse into the hydrogels; larger 
molecules, like macromolecular DNA, will remain in the voids between hydrogels, as illustrated 
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in Figure 3.1a. Upon addition of carrier oil and surfactant and agitation by vortexing, the sample 
is emulsified into droplets. Each droplet consists of a single bead surrounded by a thin shell of 
amplification reagent encapsulated in oil (Figure 3.1b). Because the particles are 
monodisperse, and provided the agitation is somewhat controlled, the sample and droplet 
volumes are monodisperse. This yields an emulsion that is equivalent to microfluidic emulsions 
commonly used for ddPCR, without microfluidics. Thus, we thermal cycle the emulsion, allowing 
amplification of the mutant and wildtype EGFR allele using common primers and dual-color 
hydrolysis probes (Figure 3.1c). In this experiment, we target a common mutation in lung 
adenocarcinomas, a 15 bp deletion on exon 19 of the EGFR gene, EGFR ΔE746-A750. The 
mutation is associated with increased resistance to EGFR inhibitors used in the treatment of 
non-small-cell lung cancers38. 
To detect the positive droplets, we use fluorescence microscopy, processing tens of 
thousands of droplets (Figure 3.1d). Analysis of fluorescence measurements using image 
processing software shows populations of droplets which contain no EGFR template, wildtype 
EGFR, mutant EGFR, and double positives (Figure 3.1e). The relative counts of the wildtype 
and mutant populations provide a measurement of variant allele frequency. To demonstrate the 
process, we use the approach to analyze two human cfDNA standards containing the mutant 
ΔE746-A750 allele at frequencies of 5% and 1% versus wildtype EGFR. In this experiment, the 
hydrogels are ~ 100 μm in diameter and monodisperse (Figure 3.2a). Following addition of the 
DNA template and amplification reagents, vortexing yields droplets with single particles 
surrounded by sample (Figure 3.2b). We thermal cycle and image the droplets for wildtype and 
mutant EGFR variant frequencies. A merged image of the fluorescein (wildtype) and Cy5 
(mutant) channels shows discrete signal from droplets containing an EGFR variant (Figure 
3.2c). We use image analysis to measure the fluorescence of the droplets (Figure 3.2d) and 
find that the measured allelic frequencies agree with the input concentration values of 5% and 
1%. These results demonstrate that PTE allows rapid and facile measurement of EGFR variant 
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alleles with accuracy comparable to ddPCR, but without the use of microfluidics and in a low-
cost and scalable format. 
 
 
Figure 3.2: Variant allele frequency analysis of cfDNA samples using a hydrogel-partitioned 
digital PCR assay. 
(a) After washing, the microgels appear translucent when suspended in an aqueous buffer. (b) 
Vortexing the microgels with fluorinated oil and PCR buffer produces monodisperse emulsions 
each containing a single microgel surrounded by a shell of amplification reagent. (c) 
Representative fluorescence micrograph of thermal cycled cfDNA emulsions containing the 
mutant EGFR allele at 5% relative frequency. (d) Scatter plots of normalized droplet fluorescence 
values for cfDNA samples containing the EGFR mutation at 5% and 1% allelic frequencies. Scale 
bars are 100 μm in all imaging panels. 
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3.4. Methods 
3.4.1. Choice of polyacrylamide microgels for PTE 
The PTE-based digital droplet assay requires monodisperse hydrogel particles for efficient 
emulsification of the DNA template and amplification reagents. A particle suspension containing 
microgels varying widely in size produces inaccurate quantification measurements, as the 
volume of the sampling container is non-uniform. In this chapter, we describe the process for 
generation of hydrogel particles using a microfluidic dropmaker. This method reliably produces 
monodisperse hydrogel suspensions for PTE, as well as gives the user control over the size of 
the particles. 
For users without microfluidic expertise or those lacking access to microfluidic 
equipment, an alternative option is to use commercially-available hydrogel microspheres (e.g., 
Bio-Rad Bio-Gel P-60 Gel, catalog no. 150-4164, or equivalent). These are typically marketed 
as components for purification columns and are therefore free of contaminants and common 
PCR inhibitors. Prior to use in the assay, users should wash the hydrogels thoroughly after 
rehydrating and remove very small and large particles by passing the suspension through a cell 
strainer. 
3.4.2. Microfluidic preparation of hydrogel particles 
The following protocol uses a microfluidic dropmaker to generate microgels for PTE. The 
dropmaker was fabricated using standard soft lithography techniques, detailed protocols for 
which can be found in prior publications2,45. For this digital droplet assay, the photoresist master 
mold should be fabricated with a feature height of 70 μm. Additionally, the oil and aqueous 
reagent channels at the dropmaking junction should have widths of 70 μm each, to produce 
droplets with an approximate final diameter of 70 μm. 
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3.4.3. Generate the hydrogel particles using a microfluidic dropmaker 
1. Prepare 1 mL of acrylamide precursor solution according to the recipe shown in      
Table 3.1. 
Table 3.1: Recipe for the acrylamide precursor solution. 
Component Final Concentration 
Tris buffer, pH 7.5 10 mM 
Ethylenediaminetetraacetic acid (EDTA) 1 mM 
Sodium chloride 15 mM 
Acrylamide 6.20% (w/v) 
N,N’-Methylenebis(acrylamide) 0.18% (w/v) 
Ammonium persulfate 0.30% (w/v) 
 
2. Prepare the oil phase by adding 1% (v/v) tetramethylethylenediamine (Sigma-Aldrich) to 
2 mL fluorinated oil (HFE-7500, 3M) containing 2% (w/w) PFPE-PEG surfactant (008-
Fluorosurfactant, Ran Biotechnologies). 
3. Load the acrylamide and oil solutions into 3-mL syringes (BD). 
4. Setup two syringe pumps (New Era, NE-501) to drive the polyacrylamide precursor 
solution and fluorinated carrier oil into the dropmaking device. Connect all syringes to 
their respective inlets and connect a piece of tubing from the outlet to a 15-mL collection 
tube. 
5. Generate droplets using flow rates of approximately 500 and 1000 μL/h for the 
acrylamide and oil phases, respectively. Pumps are controlled by a custom Python script 
(available at https://github.com/AbateLab/Pump-Control-Program). During dropmaking, 
users should periodically observe droplets under a microscope to ensure they are 
monodisperse with an average diameter of approximately 70 μm. 
6. After dropmaking, incubate the collected droplets on a heat block at 65 °C for 1 h to 
polymerize, then, proceed to the wash steps. 
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3.4.4. Wash the hydrogel droplets 
1. Prepare 100 mL of hydrogel wash buffer using the recipe shown in Table 3.2. 
Table 3.2: Recipe for the hydrogel wash buffer. 
Component Final Concentration 
Tris buffer, pH 8.0 10 mM 
Ethylenediaminetetraacetic acid (EDTA) 10 mM 
Sodium chloride 137 mM 
Potassium chloride 2.7 mM 
Triton X-100 0.1% (v/v) 
 
2. Remove excess oil from the bottom of the emulsion tube using a gel-loading pipet tip. 
3. Add an equal volume of perfluoro-1-octanol (Sigma-Aldrich) to the emulsions to dissolve 
their surfactant layer. Pipet up and down thoroughly to completely coat the emulsions. 
4. Incubate the emulsions 2 min at room temperature. 
5. Centrifuge the emulsions at 3000 × g for 1 min. After centrifugation, the hydrogels will be 
free of their surfactant layer and appear translucent. 
6. Remove excess perfluoro-1-octanol using a gel-loading pipet tip. 
7. Add 10 mL of wash buffer to the hydrogel tube. Vortex 10 s to resuspend hydrogels. 
8. Centrifuge the hydrogel suspension at 3000 × g for 3 min. 
9. Aspirate the supernatant, taking care not to disrupt the translucent hydrogel layer at the 
bottom of the tube. 
10. Repeat steps 8 and 9 two additional times to completely remove all oil from the hydrogel 
suspension. 
11.  Resuspend the beads in 5 mL of wash buffer and store at 4 °C until use in the PTE 
experiment. 
Users should examine the hydrogels under a microscope after washing to ensure complete 
removal of oil and other debris. Particles should appear translucent, spherical, and 
monodisperse, similar to those shown in Figure 3.2a. If debris or clumps are observed, the 
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hydrogel suspension can be filtered through a 100 μm cell strainer. Once prepared, hydrogels 
can be stored in wash buffer for a year or longer at 4 °C without any noticeable loss of particle 
integrity. 
3.4.5. Digital droplet PCR assay using particle-templated emulsification 
After hydrogel particle generation, PCR template and reagents are emulsified in a 
simple, microfluidic-free protocol. No further specialized equipment is required for performing 
the PTE-based digital droplet assay. The particles generated in the preceding steps provide 
sufficient hydrogels for tens of reactions (depending on reaction volume), and a typical ddPCR 
assay using PTE requires only several minutes of hands-on time to perform. 
In the following experiment, a cell-free DNA standard sourced from a commercial vendor 
(Multiplex I cfDNA Reference Standard Set, Horizon Discovery) is used to assess the 
quantification performance of the EGFR assay. The assay is readily extensible to real samples 
of human sera in which the relative frequency of the variant allele is unknown. In all cases, 
some optimization on behalf of the user is required to achieve an encapsulation rate of the 
target template within an optimal range for quantification. To limit the rate of double 
encapsulation events, an overall encapsulation rate of one template copy for every 10 droplets 
is optimal. A rough estimate of the amount of DNA template required per reaction can be 
calculated using the volume of the reaction partitions, accounting for an aqueous shell thickness 
of 5 μm around each hydrogel particle. Users are advised to first perform the assay with 
calculated amounts of template and adjust the input accordingly based on observed 
encapsulation rate after amplification. 
3.4.6. Prepare the reaction components 
1. Prepare ~ 200 μL of digital PCR solution by combining the components shown in Table 
3.3. Pipet up and down thoroughly to mix. 
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Table 3.3: Recipe for PCR amplification mix (primers shown for the EGFR ΔE746-A750 assay). 
Component (Concentration) Volume 
Final 
Conc. 
(approx.) 
Platinum Multiplex PCR Master Mix (2X) 200 µL 1X 
FWD primer (100 µM) 
5’ GGATCCCAGAAGGTGAGAAAG 3’ 1.6 µL 0.4 µM 
REV primer (100 µM) 
5’ CAGCAAAGCAGAAACTCACATC 3’ 1.6 µL 0.4 µM 
WT probe (100 µM) 
5’ /56-FAM/CGCTATCAA/ZEN/GGAATTAAGAGAAGCAACATCTCC/3IABkFQ/ 3’ 0.8 µL 0.2 µM 
MUT probe (100 µM) 
5’ /5Cy5/CGTCGCTAT/TAO/CAAAACATCTCCGAAAGC/3IAbRQSp/ 3’ 0.8 µL 0.2 µM 
Triton X-100 4 µL 2% v/v 
 
2. For each individual reaction, prepare a 50 μL aliquot of the digital PCR solution in a 1.5-
mL microcentrifuge tube, then add the predetermined volume of DNA template. To limit 
dilution of amplification reagents, the volume of added DNA template should not exceed 
5 μL. Mix thoroughly by pipetting. 
3. Prepare the polyacrylamide gels by centrifuging the stock suspension at 3000 × g for 3 
min. Remove the wash buffer supernatant by aspiration. 
3.4.7. Generate the particle-templated emulsions  
1. Transfer 50 μL of polyacrylamide gels to each microcentrifuge tube containing PCR mix 
using a wide-bore pipette tip. Pipet up and down thoroughly to mix. 
2. Incubate each reaction for 15 min at room temperature on a rotating tube mixer. 
3. Spin down each reaction at 6000 × g for 1 min. Carefully aspirate the supernatant, 
leaving only the hydrogel pellet. 
4. After removing the supernatant, add 100 μL of HFE-7500 fluorinated oil containing 2% 
(w/w) PFPE-PEG surfactant to the bottom of the microcentrifuge tube under the 
polyacrylamide gel pellet. 
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5. Vortex each tube individually at maximum power for 30 s. Slowly decrease the vortex 
speed over the course of 10 s to minimize the amount of emulsions on the tube walls. 
Allow each reaction to sit for 5 min at room temperature to allow the emulsions to settle. 
6. Using a gel loading pipet tip, remove the bottom oil phase from the tube along with the 
lower layer of emulsions. The emulsions will settle into two distinct layers, with the larger 
hydrogel-containing emulsions at the top. Rotating the microcentrifuge tube in front of a 
light source can help to identify this distinct layering. 
7. Finally, transfer 30 μL of emulsions from each reaction into labeled PCR tubes using a 
pipet. Add 40 μL of FC-40 fluorinated oil (Sigma-Aldrich) containing 5% (w/w) PFPE-
PEG surfactant to each PCR tube. At this stage, the emulsions should each contain a 
single hydrogel and appear similar to those shown in Figure 3.2b. 
8.  Thermal cycle the tubes using the following protocol: 95 °C for 2 min, 40 cycles of (95 
°C for 30 s, 58 °C for 30 s, 72 °C for 30 s), 4 °C hold. 
3.4.8. Image the thermal cycled emulsions 
1. To image each sample, carefully collect 8 μL of the oil layer and 2 μL of droplets from 
each tube using a pipet and transfer into a plastic imaging slide (Countess cell counting 
chamber slides, Thermo Fisher, catalog no. C10228, or equivalent). 
2.  Focus the image on the brightfield channel. The vast majority (> 95%) of droplets should 
contain a single hydrogel. A large number of coalesced droplets may be an indication of 
improper handling and/or thermal instability of the surfactant layer. 
3. The wildtype probe is imaged on the GFP channel (470/22 nm Ex, 510/42 nm Em) while 
the mutant allele probe is imaged on the Cy5 channel (628/40 nm Ex, 692/40 nm Em). 
Verify that the fluorescent signal from droplets on both channels is discrete, as shown in 
Figure 3.2c. 
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4. For each field of view, capture brightfield, GFP, and Cy5 channel images. Repeat for the 
entire imaging slide. Depending on the microscope hardware, this process may be 
automated. 
3.4.9. Data analysis and calculation of variant allele frequency 
The image-processing software Fiji is recommended for analysis of droplet images46. A 
brief overview of the image processing workflow is provided in this section. For a detailed 
overview of software functionality, users should consult the Fiji documentation. 
1. To image each sample, carefully collect 8 μL of the oil layer and 2 μL of droplets from 
each tube using 
2. For each field of view, import the brightfield, GFP, and Cy5 channel images into Fiji. 
3. Apply a threshold to the brightfield image such that the dark droplet boundaries are 
added to the background. 
4. Perform a particle analysis to isolate the circular inner phase of each droplet. Adjust 
particle circularity and size to select only for droplets containing a single hydrogel. 
5. Apply the particle overlay from the brightfield channel to the GFP and Cy5 channels. 
Measure the mean pixel intensity within all particles and export to graphing software (for 
example, Microsoft Excel). 
6. Repeat for multiple fields of view, until a sufficient number of droplets have been 
analyzed. 
7. In the graphing software, normalize the pixel intensities for each channel using the 
maximum and minimum values in each channel. 
8. Plot the normalized channel intensities on a 2-D scatter plot. Each quadrant should 
contain a distinct droplet population: 
- GFP−/Cy5−: droplets not containing a copy of the EGFR locus, either wildtype or 
mutant. 
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- GFP+/Cy5−: droplets containing a copy of the wildtype EGFR allele. 
- GFP−/Cy5+: droplets containing a copy of the mutant EGFR allele. 
- GFP+/Cy5+: droplets containing copies of both the wildtype and mutant EGFR 
alleles. 
The scatter plots in Figure 3.2d show the results for a single field of view from cfDNA standards 
containing 5% and 1% variant allele frequencies (VAF), where VAF is defined as 
 
In each case, the calculated VAF is close to the manufacturer's specifications, demonstrating 
the quantification performance of the ddPCR assay using PTE. No double positive (GFP+/Cy5+) 
droplets were observed for either sample. 
3.5. Conclusion 
We have demonstrated the performance of a digital droplet PCR assay capable of detecting 
variant allele frequencies as low as 1% without the use of sophisticated microfluidic equipment. 
This surpasses the quantitative limit of bulk qPCR methods, does not require experimental 
standards, and is low-cost and rapid. Experimental throughput, important for effective clinical 
implementation, is a notable advantage of this method over traditional digital PCR assays using 
dedicated microfluidic dropmaking instruments. In future studies, the degree of multiplexing can 
be pushed further by optimizing fluorescent dye color and concentration to enable detection of a 
larger number of genotypes. Furthermore, since the sensitivity of ddPCR increases as the 
sample is partitioned into more droplets, flow cytometric analysis of the droplets affords a route 
toward even greater sensitivity. 
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Chapter 4: Joint profiling of proteins and DNA in single cells reveals extensive 
proteogenomic decoupling in leukemia 
4.1. Abstract 
Current leukemia therapies target cancer cells with specific phenotypes or genotypes, 
but this assumes that either genomic mutations or immunophenotypes alone serve as faithful 
proxies for treatment response. Moreover, the heterogeneity inherent to all cancers, including 
leukemias, makes direct mapping of genotype-phenotype relationships challenging. Here, we 
present a method to genotype and phenotype single cells at high throughput, allowing direct 
characterization of proteogenomic states on tens of thousands of cancer cells rapidly and cost-
efficiently. Using this approach, we analyze the disease of three leukemia patients over multiple 
treatment timepoints and recurrences. We observe complex genotype-phenotype dynamics and 
extensive decoupling of the relationships over disease progression and response to therapy, 
illustrating the subtlety of the disease process and the inability to use genotypes as direct 
proxies for phenotypes. Our technology has enabled the first rigorous test of the prevailing 
paradigm that treatment of a disease phenotype is equivalent to treatment of its underlying 
genotype. More broadly, our results highlight the power of single-cell multiomic measurements 
to resolve complex biology in heterogeneous populations and illustrate how this information can 
be used to inform treatment. We thus expect that our methodology will find broad application to 
study proteogenomic tumor landscapes across cancers and will support the next generation of 
immunotherapy. 
4.2. Introduction 
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy prone to 
relapse that often manifests as a polyclonal ensemble of cells with distinctive genotypes but 
diverse immunophenotypes47,48. Because of this disparity, it is difficult to directly link genotypes 
to immunophenotypes beyond circumstantial evidence from epidemiologic studies. Moreover, 
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while AML blasts often exhibit immunophenotypes distinct from normal cells, with some surface 
markers even serving as therapeutic targets49, genotypes are the strongest prognostic factors, 
suggesting a weak correspondence between these domains50,51. Cellular heterogeneity is an 
intrinsic aspect of essentially all cancers, including leukemias. Because cancer cells are 
heterogeneous in genotype and phenotype, single-cell analysis provides a powerful tool for 
characterizing this complexity and thereby advancing our understanding of different cancers. 
The value of single-cell analysis is its ability to correlate co-occurrence of different features in 
individual cells, with high-throughput technologies permitting analysis of thousands of cells to 
generate rich and intricate feature maps. For example, single-cell genotyping of AML-relevant 
loci has revealed co-occurrence of mutations and mapping of the clonal relationships between 
blasts52–55. These studies, however, have yet to map DNA genotypes and phenotypes in the 
same cells, precluding direct linkage of phenotypes to the genetic mutations that drive them. 
To obtain simultaneous genotype and immunophenotype information, single cells can be 
sorted based on multi-parametric antibody analysis, and sequenced. While severely limited in 
throughput, these studies have uncovered important insights into the genetics of AML, 
identifying relevant aberrations such as single nucleotide polymorphisms (SNPs) and gene 
fusions56. Single-cell RNA sequencing (scRNA-seq) has emerged as a potentially valuable 
approach for genotype-phenotype linkage because it is cost effective and scalable53,57–59. The 
mRNA sequences provide genotype information59,60 while their counts relate phenotype8,9,61–63. 
Moreover, modern approaches are extremely high throughput, allowing characterization of 
thousands of cells. Nevertheless, genotyping from mRNA remains a challenging and error-
prone procedure that, even in the best case, provides incomplete information. For example, 
stochastic gene expression, biological biases64, and limited coverage of essential genes 
combine to make assigning a genotype more difficult than can be achieved by direct analysis of 
DNA. Moreover, since RNA methods analyze only the expressed portion of the genome, 
mutations in intronic and other non-transcribed elements, like transcription factor binding sites, 
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are omitted65,66. Thus, while several technologies have highlighted the importance of high-
throughput single cell genotype-phenotype measurements, none provide the scalability and 
precision for comprehensive and accurate mapping of these clinically valuable biomarkers.  
In this paper, we describe DAb-seq, a novel approach for joint profiling of DNA and 
surface proteins in single cells at high throughput. While existing methods attempt to obtain this 
information from the transcriptome alone, ours directly characterizes DNA for genotype and 
surface proteins for phenotype – both the gold standards in AML for these annotations. Our 
approach is thus complementary to scRNA-seq methods and, as we show, provides novel and 
important information for characterizing the disease. To illustrate the power of DAb-seq, we 
characterize the immunophenotypic and genotypic diversity underpinning AML in three patients 
at multiple timepoints, exploiting its throughput to characterize 50 DNA targets and 23 
hematopoietic markers in a total of 54,717 cells. This analysis allows tracking of proteogenomic 
dynamics for multiple patients over multiple treatments and recurrences. We identify extensive 
genotype-phenotype decoupling, observing immunophenotypic heterogeneity among cells with 
a shared pathogenic mutation and genotypically diverse cells with a convergent malignant 
immunophenotype. These findings indicate substantial variability of blast fate upon treatment in 
AML, and that independent phenotype or genotype measurements do not adequately capture 
the proteogenomic heterogeneity. More broadly, our work demonstrates how single-cell 
technologies can inform the diagnosis and treatment of AML by elucidating the complex 
interplay between DNA mutations and their effects on protein expression. 
4.3. Results 
4.3.1. Combined single-cell DNA sequencing and antibody profiling (DAb-seq) robustly 
delineates single-cell genotypes and immunophenotypic diversity 
The commercially available Mission Bio Tapestri supports highly multiplexed targeted 
sequencing of thousands of single cells and is being used across cancers for genotype and 
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lineage mapping54. While the instrument runs a flexible workflow, it does not natively support 
Abseq, a separate method we developed67 that allows characterization of single-cell surface 
proteins by sequencing, and is analogous to flow cytometry in its ability to provide 
immunophenotype information. Thus, our major technical innovation is to adapt Tapestri to 
enable simultaneous DNA and Abseq analysis. As in our published Abseq approach, DAb-seq 
begins with immunostaining of a cell suspension using a mixture of antibody-oligo conjugates 
(Figure 4.1a). Each antibody is associated with a known oligo tag; thus, when cells are stained 
with a pool of tagged antibodies, each cell is bound with a combination of antibodies and their 
tags based on surface protein profile. To characterize the profile, the tags must be sequenced 
and counted which, in flow cytometry, is analogous to measuring fluorescence of the dyes 
associated with each antibody, except that photon counting is replaced with tag counting. 
 
Figure 4.1: The DAb-seq workflow. 
(a) Bone marrow aspirates of patients with AML contain healthy and malignant cells that exhibit 
diverse genotypes and immunophenotypes. These cells are stained with antibodies labeled with 
DNA tags. (b) Stained cells are paired and encapsulated with a barcode bead on a Mission Bio 
Tapestri instrument. (c) In each droplet, a PCR labels antibody tags and genomic DNA targets 
simultaneously with a unique cell index. (d) Sequencing the barcoded amplicons and antibody 
tags yields coupled single-cell immunophenotype and genotype data for thousands of cells. 
 
The stained cells are processed through a modified Tapestri workflow to amplify and 
barcode genomic targets and surface-bound antibody tags. The workflow follows a two-step 
protocol to lyse cells and digest chromatin, making the genome accessible to amplification; the 
droplets are then subjected to a multiplex PCR to simultaneously amplify the genomic targets 
and capture antibody tags, labeling them with a droplet barcode relating sequences from the 
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same cell (Figure 4.1b). For genotype, we target recurrently mutated genomic DNA loci in AML 
with primers containing a unique cell barcode against 50 amplicons spanning 19 genes. The 
primers and PCR conditions are tuned to enable uniform and quantitative amplification of all 
targets, since count information is necessary for accurate genotype and immunophenotype 
characterization. These primers also capture antibody tags from a 23-plex immunophenotyping 
panel based on those used in clinical minimal residual disease studies68,69 (Figure 4.1c). 
Sequencing yields a multiomic data set where each cell is represented by two vectors and 
which can be visualized as a low-dimensional embedding (Figure 4.1d). 
Peripheral blood mononuclear cells (PBMCs) comprise a diverse and well-understood 
population easily obtained from a blood draw, and thus provide an excellent sample by which to 
assess the effectiveness of DAb-seq for mapping hematopoietic immunophenotypes. When 
applied to PBMCs from a healthy donor, we obtain expected cell subsets across blood 
compartments, identifying both rare and abundant cells in peripheral blood (Figure 4.2a,b). To 
test single-cell genotyping capability, we also perform DAb-seq on a mixture of three cell lines 
derived from distinct hematopoietic lineages (Jurkat, Raji, K562) with documented mutations in 
the targeted genomic regions covered by our single-cell DNA sequencing panel70. For all 
genetic variants, we assign genotype calls to each individual cell: homozygous wildtype, 
heterozygous alternate, or homozygous alternate. We observe the expected correspondence 
between single-cell genotypes and phenotypes, as cells of the same genotype segregate within 
a common immunophenotypic cluster (Figure 4.2c,d). Notably, we also find that DAb-seq’s 
genotyping is sufficiently sensitive to differentiate the cells based on zygosity of a given 
mutation (Figure 4.2d). These results show that DAb-seq can simultaneously profile genotype 
from direct analysis of genomic DNA and immunophenotype from barcoded antibodies. 
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Figure 4.2: DAb-seq enables simultaneous discrimination of single cells by their 
immunophenotype and genotype. 
(a) DAb-seq workflow performed on PBMCs from a healthy donor using a panel of 23 antibodies. 
Leiden clustering and two-dimensional UMAP embedding of the antibody tag data reveals 
expected blood compartments. Compartments are annotated based on detected marker 
expression. (b) Heatmap of the corrected log-transformed antibody counts for each cell and 
antibody. Cells are ordered based on Leiden clusters. Overlay of corrected log-transformed 
antibody counts with the UMAP embedding highlights compartment-specific expression. (c) 
Correspondence of antibody signal with genomic polymorphisms in DAb-seq experiments tested 
on a mixture of three cell lines and a panel of six antibodies. Cells cluster by antibody signal as 
shown in the UMAP embedding. (d) Detected single nucleotide polymorphisms in these cells map 
to the phenotypic cell clusters as shown in the UMAP embedding and a heatmap, where rows 
correspond to single cells. The first column of the heatmap indicates assigned phenotype cluster, 
and the remaining columns indicate the genotyping call at the labeled loci. 
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4.3.2. NPM1-mutated cells persist across therapy timepoints with a static immunophenotype 
AML therapies targeted to cell surface proteins require ubiquitous expression of the 
target marker on the malignant cells. We therefore reason that mutated cells should robustly 
associate with a common targeted phenotype in patients responsive to this therapy. To 
investigate this, we perform DAb-seq on 21,952 total cells from bone marrow aspirates of a 
patient with AML receiving gemtuzumab, a CD33-targeted therapy, across four treatment 
timepoints (Figure 4.3a). This patient received multiple rounds of chemotherapy, including a 
stem cell transplantation, prior to the first timepoint sampled in this study (Table 4.1). In the 
single-cell DNA genotyping data, we identify a recurrent frameshift mutation in the NPM1 gene 
(NPM1mut) across relapse, salvage therapy, and progression timepoints. In addition, the NPM1 
mutation is found to always co-occur with a mutation at the DNMT3A locus (Figure 4.3a). 
Gemtuzumab targets CD33+ cells, which are extinguished at the remission timepoint71. To 
examine the immunophenotypic profile of the NPM1mut blast population, we plot single-cell 
CD33 and CD34 values with NPM1 mutation status across timepoints (Figure 4.3b). The 
proportion of NPM1mut cells in the CD34- and CD34+ compartments does not vary extensively 
across treatments, suggesting the lack of a therapeutic response in the blast immunophenotype. 
CD33+ myeloid cells targeted by the drug are absent at remission. 
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Table 4.1: AML patient clinical histories. 
Gemtuzumab Patient Pediatric Patient Gilteritinib Patient 
Date Notes Date Notes Date Notes 
Dec-14 Diagnosis Nov-15 Diagnosis Oct-18 Diagnosis 
  Treatment: cytarabine + idarubicin   
Treatment: per study 
AAML1031 with 
bortezomib (cytarabine, 
daunorubicin, 
etoposide, bortezomib) 
  Treatment: cytarabine/daunorubicin 
Jan-15 End of induction persistent disease Jan-16 Remission Nov-18 
End of induction therapy 
(persistent NPM1) 
Feb-15 Gilteritinib   
Treatment: 
consolidation per 
AAML1031 (cytarabine, 
etoposide, 
mitoxantrone, 
bortezomib) 
Dec-18 HDAC + glasdigib x2 
Mar-15 Persistent disease Sep-16 Relapse Jan-19 Persistent NPM1 
Apr-15 
Treatment: 
clofarabine, 
cytarabine 
  Feb-19 Treatment: azacitidine + venetoclax 
May-15 Remission   Mar-19 Recurrence with new FLT3-ITD 
Jun-15 HSCT   Apr-19 Treatment: FLAG-Ida 
Aug-15 Recurrence   May-19 Recurrence 
  Treatment: sorafinib + azacitidine x 6 
    Treatment: gilteritinib 
Jan-16 Treatment: sorafinib maintenance 
  Jun-19 Prior to HSCT 
Mar-19 Relapse 
Key of acronyms 
  
*HSCT= Hematopoetic stem cell 
transplant 
*DLI = donor lymphocye infusion 
*FLAG = fludarabine, cytarabine, G-
CSF 
*ida = idarubicin 
  
  
Treatment: 
azacitidine + 
venetoclax 
  
Apr-19 End of induction: persistent disease 
  
  
Treatment: 
azacitidine + 
venetoclax 
  
May-19 Progressive disease   
  
Treatment: 
gemtuzumab + 
gilteritinib 
  Indicates sample analyzed 
by DAb-seq 
Jun-19 DLI     
Jun-19 Remission     
 
In all timepoints for this patient, our analysis suggests an equivalence between the 
dominant blast genotype and corresponding phenotype. To further explore this relationship 
between genotype and phenotype, we visualize the high-dimensional single-cell 
immunophenotype as a Uniform Manifold Approximation and Projection72 (UMAP) embedding of 
the antibody data (Figure 4.3c). Cells within single antibody clusters originate from different 
timepoints, highlighting the stability of normal and malignant immunophenotypes over time.  
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Figure 4.3: AML blasts exhibit a stable genotype and phenotype through treatment. 
(a) DAb-seq performed on four bone marrow aspirates of a patient with AML during disease 
progression as indicated in the fishplot (black lines). The patient received multiple rounds of 
chemotherapy prior to the experiment (Table 4.1). The fraction of blast cells with NPM1 
W288Cfs*12 (NPM1mut) mutation for each sampled time point detected by DAb-seq are shown in 
red. (b) Scatter plots with kernel densities show CD33 and CD34 signal for all cells (grey) and 
NPM1mut cells (red) for each of the sampled time points. The percentage of normal and mutant 
cells within each gate are listed. Virtually gating cells highlights a persisting CD33+ blast 
population which is eradicated with gemtuzumab, a CD33-targeted therapy. (c) UMAP embedding 
based on the log-transformed and corrected antibody counts from all cells labeled by timepoint 
indicates that the high-dimensional immunophenotype of the blasts is stable over the sampled 
timepoints. (d) The genotype of each cell at the NPM1 locus is plotted as a kernel density estimate 
using the UMAP coordinates from (c). Antibody signals enriched among malignant and normal 
populations are plotted as kernel densities using all cells and labeled by genotype. 
 
When we overlay NPM1 genotype on the immunophenotype UMAP space, we find a 
clear association between a single malignant immunophenotype composed of CD33+ cells with 
NPM1 mutation status, with variable expression of CD34, CD38, and CD117 in this population 
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(Figure 4.3d). Indeed, this is in agreement with previous observations in flow cytometric studies 
where blast cells have been found to uniformly express CD33 and variably express CD34, 
CD38, and CD11773. Among the NPM1wt cells, we identify classical blood cell markers including 
CD3 and CD5 (lymphocyte), CD15 (monocyte), and CD56 (natural killer). Taken together, in this 
patient, DAb-seq confirms elimination of CD33+ cells by gemtuzumab treatment and reveals a 
strong correspondence between genotype and phenotype across timepoints. 
4.3.3. Genotypic subclones form overlapping subsets across an immunophenotypic continuum 
To investigate whether such tight genotype-phenotype association is a universal feature 
of AML, we apply DAb-seq to a pediatric patient who underwent induction and consolidation 
chemotherapy, but ultimately relapsed (Table 4.1). We identify two mutually exclusive KRAS 
and FLT3-mutated clones at diagnosis and relapse (KRASmut, FLT3mut). The FLT3mut population, 
although the minor subclone at diagnosis comprising just 43 of 4,563 cells (0.94%) compared to 
1,539 cells (33.7%) for the KRASmut variant, dominates at relapse (6,800 of 7,516 cells, 90.5%) 
(Figure 4.4a). Immunophenotypically, we also identify a third subset comprising 
KRASWT/FLT3WT cells expressing a blast-like CD33+CD38+ immunophenotype with no 
identifiable DNA mutations in the targeted loci. When we group cells from all timepoints by 
genotype, pathogenic blasts display variable patterns in immunophenotype, with no clear 
mapping between the two (Figure 4.4b).  
In the absence of an obvious genotype-phenotype mapping for this patient, we sought to 
investigate the underlying relationship between these domains. Using UMAP, we project the 
antibody data into two dimensions, coloring the points according to genotype (Figure 4.4c). We 
observe a single immunophenotypic compartment with incomplete separation between 
genotypes. To estimate antibody profile expression within the blast compartment continuum, we 
identify the dominant gradient in the phenotypic space, ordering all points along the gradient. 
We then calculate the local average antibody and genotypic composition for neighboring cells 
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(Figure 4.4c,d) (also see section 4.5: Methods). As expected, many markers are anticorrelated 
(CD11b, CD33, CD56) or correlated (CD15) with the principal immunophenotypic gradient. Less 
trivially, genotypic compositions vary along the gradient, with KRASmut clone frequencies 
anticorrelated and FLT3mut correlated (Figure 4.4d). Nevertheless, genotype composition never 
completely separates into individual clonal populations, making it impossible to define distinct 
genotype-phenotype clusters; consequently, technologies profiling one modality, such as 
genotyping or immunophenotyping, cannot adequately capture the heterogeneity inherent to this 
case of AML. 
 
 
Figure 4.4: Distinct genetic subclones form an overlapping immunophenotypic continuum in a 
case of pediatric AML. 
(a) Three timepoints sampled with DAb-seq during treatment comprise a mixture of independent 
clones (KRAS G13D heterozygous blasts, yellow; FLT3 D835Y blasts, red). The wildtype 
compartment contains additional cells with a blast-like immunophenotype lacking detectable 
mutations. (b) Heatmap of log-transformed corrected antibody counts and genotyping calls for the 
KRAS and FLT3 loci for each cell across all timepoints. The heatmap is grouped by genotype. 
Cells with wildtype genotype but blast-like immunophenotype are labeled separately. (c) UMAP 
embedding of all cells from all time points based on log-transformed corrected antibody counts. 
Color indicates mutation status as in a. The blast compartment is overlaid with a spline 
approximating the gradient of the 2nd principal component of the antibody count matrix (shown in 
inlet figure) and indicates a gradual change in immunophenotype. (d) Moving average expression 
of antibodies and fraction of mutated cells sorted by the 2nd principal component of the antibody 
count matrix. The overlapping phenotypic continuum between the genetically distinct blast clones 
is apparent. 
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4.3.4. FLT3 inhibitor therapy induces erythroid differentiation in a case of AML 
Our first two cases feature either a strong genotype-phenotype correlation (Patient 1) or 
mixed genotyping comprising a single immunophenotype (Patient 2). Thus, for our final case, 
we analyze a patient treated with gilteritinib, a FLT3 inhibitor therapy reported to promote in vivo 
differentiation of myeloid blasts. This treatment is thought to disperse distinct genotypes into 
multiple immunophenotypes, although the terminal lineage of the cells remains poorly 
understood74–76. Accordingly, we hypothesize DAb-seq should allow tracking of 
immunophenotypic dispersal and confirmation of their terminal hematopoietic lineage. We 
analyze 18,287 cells across treatment timepoints, beginning at diagnosis, discovering a 
subclone with co-mutated DNMT3A and NPM1 (Figure 4.5a; Table 4.1). Following 
cytarabine/daunorubicin induction therapy, a fraction of DNMT3Amut cells remain at remission. At 
relapse and after treatment with the FLT3 inhibitor gilteritinib (“FLT3 Inhibitor”), most cells 
contain a 24-bp FLT3 internal tandem duplication (ITD), in addition to the initial DNMT3A and 
NPM1 mutations. The genotypic structure inferred from the single-cell data indicates a linear, 
branching hierarchy of sequentially acquired mutations in response to therapy. To explore the 
immunophenotypic features of this patient’s disease, we integrate cells from all timepoints and 
construct a UMAP representation using the antibody data (Figure 4.5b). We cluster this data 
using the Leiden method for cluster detection, an improved algorithm over Louvain 
modularity77,78, and manually annotate with phenotypic labels corresponding to hematopoietic 
lineage from the antibody data (Figure 4.5c). We identify three blast populations expressing 
high levels of CD33 and CD38, a monocytic population expressing CD15 and CD16, and 
erythroid and lymphoid clusters with elevated CD71 and CD3. As expected, samples across 
treatment timepoints comprise a mixture of immunophenotypically normal and blast-like cells. 
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Figure 4.5: Decoupling of blast phenotype and genotype in response to FLT3 inhibitor therapy. 
(a) Fishplot showing observed fraction of cells with distinct genetic mutations for each sampled 
time point. The co-occurrence of the three mutations in the single-cell data is consistent with a 
linear model of mutation accumulation. (b) UMAP embedding of all cells based on measured 
antibody signal. The cells segregate into six distinct phenotypic clusters with multiple blast 
compartments. (c) Average expression of each cell cluster for a selection of markers. (d) Top row: 
Same UMAP embedding as in b given as grey outline. For each sampled time point, observed 
cells are plotted and colored according to the detected genotype. Blasts distribute among multiple 
phenotypic compartments in the final time point following FLT3 inhibitor treatment. Middle row: 
Kernel density plot of the CD33 antibody signal resolved by time point and genotype. Cells from 
genotypic compartments with less than 10 cells per time point are not plotted. Bottom row: Bar 
chart depicting genotypic composition of each phenotypic cluster in b resolved by time point. 
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Hypothesizing that different therapies should yield different genotype-phenotype 
coupling patterns, we sought to characterize how mutated and normal cells distribute across 
immunophenotypic clusters. For each timepoint, we thus label cells in UMAP space according to 
DNA genotype and generate density distributions of CD33 signal, a pan-myeloid marker (Figure 
4.5d). We also evaluate counts of phenotype cluster membership in each timepoint, subdivided 
by DNA genotype. At diagnosis, cells mutated at both the DNMT3A and NPM1 locus reside 
primarily in the Blast 1 cluster (81.8% of DNMT3Amut/NPM1mut cells) and express high levels of 
CD33. A secondary clone mutated exclusively at the DNMT3A locus exhibits comparable CD33 
expression and resides mainly in the Blast 1 and monocytic clusters (62.5% and 27.7% of 
DNMT3Amut cells, respectively). At remission, the same DNMT3Amut clone is identified but with 
decreased CD33 expression and a primarily monocytic immunophenotype (92.7% of 
DNMT3Amut cells) co-localizes with cells of normal genotype, consistent with clonal 
hematopoiesis of a pre-leukemic clone79,80. A newly acquired FLT3-ITD clone emerges in high 
numbers at relapse (99.8% of genotyped cells), coinciding with a phenotypic shift of cells to the 
CD33+ Blast 2 cluster. Following FLT3 inhibitor treatment, the same FLT3-ITD clone persists but 
exhibits a transformed immunophenotype, as evidenced by membership of the FLT3 clone in 
multiple immunophenotypic clusters. The new FLT3-ITD immunophenotype is primarily erythroid 
(82.2% of FLT3-ITD cells), with minor fractions in the Blast 3 and monocytic compartments 
(11.1% and 4.84% of FLT3-ITD cells, respectively). Furthermore, the FLT3-ITD clone at relapse 
lacks uniform CD33 expression, indicating that this clone is no longer restricted to the myeloid 
compartment. Taken together, these findings support the model of terminal erythroid 
differentiation of blasts in a case of leukemia treated with gilteritinib. In agreement with a recent 
study76, proteogenomic analysis by DAb-seq challenges a prior report of gilteritinib-induced 
terminal differentiation towards a myeloid fate75. DAb-seq elucidates the rich and complex 
dynamics of this process and illustrates how distinct DNA genotypes can fractionate into 
multiple phenotypic identities in response to treatment. 
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4.4. Discussion 
Through its ability to jointly profile DNA and immunophenotype, DAb-seq captures the 
complexity of proteogenomic states underlying AML. Analysis of multiple patients over 
timepoints and treatments demonstrates the plasticity of the disease and the complex and 
unpredictable way it progresses in different contexts. In a patient with extensive clinical history 
including multiple rounds of chemotherapy, we found a robust relationship between mutant 
NPM1 cells and a malignant phenotype; this suggested that a single CD33-targeted therapy 
would eradicate the blast population, as indeed it did. By contrast, in a separate case of 
pediatric AML, we observed that genetically distinct populations shared overlapping 
immunophenotype, demonstrating that this domain alone is insufficient for characterizing how 
cells are genetically programmed and may, consequently, respond to treatment. In the final 
case study, we observed the opposite scenario, in which treatment by gilteritinib induced 
mutationally similar cells to disperse into different myeloid compartments, highlighting the 
challenge of targeting these malignant cells for eradication. Our results thus demonstrate that 
genotype or immunophenotype alone is insufficient to predict the evolution of proteogenomic 
states in AML.  
DAb-seq employs targeted primers to amplify specific genomic regions and panels of 
antibodies. While both readouts enable massive multiplexing of queried targets, practical and 
economic constraints necessitate a priori knowledge of which loci and epitopes to profile. As 
such, the strength of DAb-seq is not unbiased feature discovery, as with scRNA-seq, but rather 
sensitive and precision analysis of actionable information. Furthermore, as with all targeted 
methods of DNA genotyping, DAb-seq cannot exclude the possibility that disease-relevant 
mutations occur beyond the sequenced loci or in immunophenotypic markers not included in the 
panels. In the case of pediatric AML, it is therefore impossible for us to conclude if the 
FLT3wt/KRASwt blast population is driven by epigenetic changes or unmapped genomic 
aberrations. Nevertheless, the sensitivity of DAb-seq, and its low genotyping drop-out, allows 
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identification of co-occurring mutations, including heterozygous mutations that are notoriously 
difficult for RNA-based approaches. Moreover, DAb-seq firmly places genomic mutations in 
understood phenotypic contexts, which is vital for understanding how they program the disease 
and, ultimately, treatments select for them. 
In the era of personalized medicine, treatment decisions are increasingly based on DNA 
mutation status, such as targeted EGFR inhibitors or protein expression like HER2 or PD-L1 
status. To fully leverage the capabilities of modern profiling techniques, however, information 
across all available domains must be integrated to optimize the therapeutic strategy for a given 
patient. Indeed, our findings underscore the importance of utilizing both genotype and 
immunophenotype to fully characterize disease and assess efficacy of treatment. For example, 
CAR T-cell therapy derives specificity from protein expression, yet would fail to elicit a complete 
response if pathogenic genotypes were distributed across multiple phenotypic clusters. Such a 
scenario would require joint single-cell profiling as in DAb-seq to unravel. As multiomic single-
cell technologies like DAb-seq become available, it will be feasible to use comprehensive 
precision analysis to deconvolute the subtlety of each patient’s cancer and thereby select the 
best treatment regimen. 
4.5. Methods 
4.5.1. Conjugation of antibodies to oligonucleotide barcodes 
Monoclonal antibodies were conjugated to azide-modified oligonucleotides using a 
copper-free click chemistry reaction as described previously81. Monoclonal antibodies were 
resuspended to 100 μg in 100 μL PBS. Antibodies were incubated with DBCO-PEG5-NHS Ester 
linker (Click Chemistry Tools, cat. no. A102P) at a 4:1 molar ratio linker:antibody for 2 h at room 
temperature. Following incubation, the antibody-linker solution was washed once in a 50 kDa 
cellulose spin filter (Millipore Sigma, cat. no. UFC505024). DNA oligonucleotides with a 5’ azide 
modification (Integrated DNA Technologies) were reconstituted in water and added to the 
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washed antibodies at a 2.5:1 molar ratio oligonucleotide:antibody. Following a 16 h incubation, 
the conjugated antibodies were washed three times in a 50 kDa filter to remove unreacted 
oligonucleotides. All antibody conjugates were run on a Bioanalyzer Protein 230 electrophoresis 
chip (Agilent Technologies, cat. no. 5067-1517) to verify successful conjugation. 
4.5.2. Cell culture and PBMC processing for control experiments 
The following three cell lines were used in the initial control experiment: Raji (ATCC, 
CCL-86), Jurkat (ATCC, TIB-152), K562 (ATCC, CCL-243). Cells were cultured under the 
supplier’s recommended conditions. PBMCs from a single healthy donor were sourced 
commercially (iXCells Biotechnologies, cat. no. 10HU-003) and stored at -80°C until use. Prior 
to staining, the cultured cell lines and PBMCs were washed once in PBS with 5% fetal bovine 
serum (FBS) (Thermo Fisher, cat. no. 10082147). For the control experiment, the three cell lines 
were combined at an equal ratio. 
4.5.3. Collection of patient samples 
Patients included in this study were treated at the University of California, San Francisco 
(UCSF), and peripheral blood or bone marrow was stored in the UCSF tumor bank. Samples 
were processed immediately after collection to isolate mononuclear cells. Sample collection was 
in accordance with the Declaration of Helsinki under institutional review board-approved tissue 
banking protocols. Written informed consent was obtained from all patients. 
4.5.4. Thawing patient samples 
A protocol was optimized to maximize recovery of viable cells from patient samples. 
Cryovials containing patient tissue (peripheral blood or bone marrow aspirate) were warmed by 
hand and carefully transferred dropwise to a 50 mL tube containing 40 mL of cold DMEM media 
(Thermo Fisher, cat. no. 11995040) with 20% FBS and 2 mM EDTA. The tube was centrifuged 
at 700 rpm at 4°C for 7 min with no brake. The supernatant was discarded, and the cells were 
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resuspended in 10 mL of warmed RPMI-1640 media (Thermo Fisher, cat. no. A1049101) with 
10% FBS. The solution was strained through a 70 μm cell strainer (Corning, cat. no. 431751) to 
remove any large cell aggregates and the tube was centrifuged a second time at 700 rpm at 4°C 
for 5 min with low brake. The supernatant was discarded, and the cells were resuspended in 
PBS with 5% FBS for staining. 
4.5.5. Cell staining using oligonucleotide-conjugated antibodies 
For each sample, 2 million cells were added to a 5 mL DNA LoBind tube (Eppendorf, 
cat. no. 0030108310), centrifuged at 400 x g for 4 min, and resuspended in 180 μL PBS with 
5% FBS. Cells were blocked for 10 min on ice following addition of 10 μL Fc blocking solution 
(BioLegend, cat. no. 422301), 4 μL of a 1% dextran sulfate solution (Research Products 
International, cat. no. D20020), and 4 μL of 10 mg/mL salmon sperm DNA (Invitrogen, cat. no. 
15632011). Cells were stained for 30 min on ice with 0.5 μg of each conjugated antibody. After 
incubation, five rounds of washing were performed to remove excess antibody. For each wash, 
5 mL PBS with 5% FBS was added to the tube and centrifuged at 400 x g for 4 min. Stained 
cells were resuspended in Mission Bio cell buffer at a final concentration of 3 M/mL prior to 
microfluidic encapsulation. 
4.5.6. Microfluidic single-cell DNA genotyping and antibody capture  
A commercial single-cell DNA genotyping platform (Mission Bio, Tapestri) was used to 
perform microfluidic encapsulation, lysis, and barcoding according to the manufacturer’s 
protocol for the acute myeloid leukemia V1 panel. Where noted, modifications were made to 
enable co-capture of oligonucleotide-labeled antibodies. Stained cells were loaded into a 
microfluidic cartridge and co-encapsulated into droplets with a lysis buffer containing protease 
and mild detergent. Droplets were incubated in a thermal cycler for 1 h at 50°C to digest all 
cellular proteins, followed by 10 min at 80°C to heat-inactivate the protease.  To enable antibody 
capture during the barcoding stage, the antibody tags were designed with 3’ complementarity to 
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one of the RUNX1 gene forward primers and the corresponding reverse primer was omitted 
from the reverse primer pool. Lysed cells in droplets were transferred to the barcoding module 
of the microfluidic cartridge in addition to polymerase mix, the modified reverse primer pool, 
barcoded hydrogel beads, and oil for droplet generation. The droplets were placed under a UV 
lamp (Analytik Jena, Blak-Ray XX15L) for 8 min to cleave the single-stranded PCR primers 
containing unique cell barcodes from the hydrogel beads. To amplify DNA targets and capture 
antibody tags, droplets were thermal cycled using the following program: 95°C for 10 m; 20 
cycles of (95°C for 30 s, 72°C for 10 s, 61°C for 4 min, 72°C for 30 s); 72°C for 2 min; 4°C hold. 
4.5.7. Single-cell DNA amplicon and antibody tag sequencing library preparation 
Recovery and cleanup of single-cell libraries proceeded according to the Mission Bio V1 
protocol with additional modifications for antibody library preparation. The 8 PCR tubes 
containing barcoded droplets were pooled as pairs and treated with Mission Bio Extraction 
Agent. Water was added to each tube and the aqueous fraction transferred to a new 1.5 mL 
DNA LoBind tube. Ampure XP beads (Beckman Coulter, cat. no. A63881) were added at a 
0.75X volume ratio beads:PCR product for size selection. The supernatant from the size 
selection step, containing library fragments shorter than ~200 bp, was retained and used for 
antibody library preparation, while the remaining beads with bound DNA panel library fragments 
were washed twice with 80% EtOH and eluted in 30 μL water. A biotinylated capture 
oligonucleotide (/5Biosg/GGCTTGTTGTGATTCGACGA/3C6/, Integrated DNA Technologies) 
complementary to the 5’ end of the antibody tags was added to the retained supernatant to a 
final concentration of 0.6 μM. The supernatant-probe solution was heated to 95°C for 5 min to 
denature the PCR product, then snap-cooled on ice for probe hybridization. 10 μL of 
streptavidin beads (Thermo Fisher, cat. no. 65001) were washed according to the 
manufacturer’s protocol and added to each tube of PCR product. Following a 15 min incubation 
at room temperature, the beads were isolated by magnetic separation, washed two times in 
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PBS, and resuspended in 30 μL water. PCR was performed on the purified DNA panel and 
antibody tags to produce sequencing libraries. For each tube of purified DNA panel, 50 μL 
reactions were prepared containing 4 ng of barcoded product in 15 μL water, 25 μL Mission Bio 
Library Mix, and 5 μL each of custom P5 and Nextera P7 primers (N7XX), both at 4 μM stock 
concentration. The reactions were thermal cycled using the following program: 95°C for 3 min; 
10 cycles of (98°C for 20 s, 62°C for 20 s, 72°C for 45 s); 72°C for 2 min; 4°C hold. For each 
tube of purified antibody tags, identical reactions were prepared, instead using 15 μL bead-
bound template, 5 μL antibody tag-specific P7 primer at 4 μM, and 20 cycles of amplification. 
Following amplification, both the DNA panel and antibody tag libraries were cleaned with 0.7X 
Ampure XP beads and eluted in 12 μL water. 
4.5.8. Next-generation sequencing 
All DNA panel and antibody tag libraries were run on a Bioanalyzer High Sensitivity DNA 
electrophoresis chip (Agilent Technologies, cat. no. 5067-4626) to verify complete removal of 
primer-dimer products. Libraries were quantified by fluorometer (Qubit 3.0, Invitrogen) and 
sequenced on Illumina next-generation sequencing platforms with a 20% spike-in of PhiX 
control DNA (Illumina, cat. no. FC-110-3001). All sequencing runs used a dual-index 
configuration and a custom Read 1 primer (5’ 
GCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGTAG 3’, Integrated DNA Technologies). 
The 3-cell control sample was sequenced on an Illumina MiSeq using a v2 300-cycle kit in 
2x150 bp paired-end mode (Illumina, cat. no. MS-102-2002). For the patient samples, DNA 
panel and antibody tag libraries were sequenced separately to maximize cost-effectiveness. 
DNA panels were sequenced with an Illumina NovaSeq 6000 SP 300-cycle Kit (Illumina, cat. no. 
20027465) in 2 x 150 bp paired-end mode. Antibody tag libraries were sequenced with an 
Illumina NextSeq 550 75-cycle High Output Kit (Illumina, cat. no. 20024906) in paired-end 
mode, using 38 cycles for Read 1 and 39 cycles for Read 2.  
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4.5.9. Bioinformatic pipeline for single-cell DNA genotyping and antibody tag counting 
Sequencing data was processed using a custom pipeline available on GitHub (see Code 
Availability). For all reads, combinatorial cell barcodes were parsed from Read 1 using cutadapt 
(v2.4) and matched to a barcode whitelist. Barcode sequences within a Hamming distance of 1 
from a whitelist barcode were corrected. 
For the DNA genotyping libraries, reads with valid barcodes were trimmed with cutadapt 
to remove 5’ and 3’ adapter sequences and demultiplexed into single-cell FASTQ files using the 
script “demuxbyname” from the BBMap package (v.38.57). Valid cell barcodes were selected 
using the inflection point of the cell rank plot in addition to the requirement that 60% of DNA 
intervals were covered by a minimum of 8 reads. FASTQ files for valid cells were aligned to the 
hg19 build of the human genome reference using bowtie2 (v2.3.4.1). The single-cell alignments 
in BAM format were filtered (properly mapped, mapping quality > 2, primary alignment), sorted, 
and indexed with samtools (v1.8). GVCF files were produced for all cells using HaplotypeCaller 
from the GATK suite (v.4.1.3.0). Joint genotyping was performed on all genomic intervals in 
parallel (excluding primer regions) using GATK GenotypeGVCFs. For longitudinal patient 
samples, cells from all timepoints were joint genotyped as a multi-sample cohort. Genotyped 
intervals from all cells were combined into a single variant call format (VCF) file, and multiallelic 
records were split and left-aligned using bcftools (v1.9). Variants were annotated with ClinVar 
metadata (v.20190805) and SnpEff functional impact predictions (v4.3t). Variant records for all 
cells were exported to HDF5 format using a condensed representation of the genotyping calls 
(0: wildtype; 1: heterozygous alternate; 2: homozygous alternate; 3: no call). 
The antibody tag libraries were processed identically for cell barcode demultiplexing. For 
reads with valid cell barcodes, 8 bp antibody barcodes and 10 bp unique molecular identifiers 
(UMIs) were extracted from Read 2 using cutadapt with the requirement that all UMI bases had 
a minimum quality score of 20. Antibody barcode sequences within a Hamming distance of 1 
from known antibody barcodes were corrected. UMI sequences were grouped by cell and 
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antibody and counted using the UMI-tools package (v.0.5.3, “adjacency” method). UMI counts of 
antibodies for each cell barcode were exported in tabular format for further analysis. 
4.5.10. Cell and genotype filtering 
Cell barcodes were additionally filtered according to antibody counts. Valid barcode 
groups were required to have a minimum of 100 antibody UMIs by the adjacency counting 
method and a maximum IgG1 count no greater than five times the median IgG1 count of the 
associated DAb-seq experiment. For each valid cell barcode, all variants were filtered according 
to the quality and sequence depth reported by GATK. Genotyping calls were required to have a 
minimum quality of 30 and total depth of 10; variant entries below these thresholds were marked 
as “no call” and excluded from analyses. 
4.5.11. Antibody-based embedding and clustering 
To correct for technical effects in the raw antibody counts and batch variability between 
experiments from the same patient but different time points, a linear regression over all cells 
from the same patient was performed. This approach is similar to those employed in single-cell 
RNA-seq normalization procedures82, which attempt to reduce technical and biological noise in 
expression data by treating variables (sequencing depth, cell cycle, etc...) as regressors in a 
linear model. For DAb-seq antibody data, to all entries cij of the UMI corrected antibody count 
matrix c, where i is the cell index and j the antibody index, one pseudocount was added and the 
matrix was log-transformed. A matrix of quality metrics q with cells as rows and four columns 
(total antibody reads, total antibody counts after UMI correction, IgG1 count and total amplicon 
reads) was log-transformed, column-wise normalized, and mean-centered. A singular value 
decomposition was performed on the transformed matrix q and the left-singular vectors retained 
as design matrix. Each column vector cj was then regressed with either the first three, two, or 
one left-singular vectors, for patient samples, PMBC or cell lines respectively as regressors. The 
vector of residuals uj is then the corrected antibody signal of antibody j (Figure 4.6). 
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Figure 4.6: Antibody count bias correction by linear regression. 
(a) Raw UMI counts for each antibody and cell are plotted versus total antibody count from the 
same cell. A clear correlation between the two is visible. A similar slope is visible for the isotype 
control (bottom row, rightmost column), suggesting technical bias. (b) Same plots as in (a) after 
correcting for global droplet performance by linear regression. Correlation with total antibody 
counts is reduced. In both corrected and uncorrected plots for many of the markers, two clusters 
of cells are prominent, representing low- and high-expressing cells. 
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A UMAP embedding in two dimensions of the corrected antibody signal was done in 
Python 2.7 using the umap-learn72 (v0.3.10) and scanpy83 (v.1.4.4.post1) packages, with the 
minimum distance parameter set to 0.1 for the pediatric patient and 0.2 for all other samples 
and default parameters otherwise. To construct the underlying nearest neighbor graph from the 
corrected antibody count matrix, 15 or 16 nearest neighbors based on the first 16 to all principal 
components were used. The scanpy implementation of the Leiden algorithm77 with resolution 
set to 0.1 for the three cell line experiment and 1 otherwise was used to assign cells to 
phenotypic compartments. A comparison of single-cell UMAP plots derived from raw and linear 
regression-corrected antibody counts is shown in Figure 4.7. The corrected antibody counts 
produce less dispersed, discrete cell clusters due to a reduction in noise from amplification bias 
and nonspecific antibody binding. 
 
 
Figure 4.7: Single-cell UMAP plots derived from raw and corrected antibody counts for the 
patient treated with CD33-targeted therapy. 
(a) UMAP plot of raw single-cell antibody counts, using only the UMI-corrected values. (b) UMAP 
plot of single-cell antibody counts, corrected by linear regression. 
 
For the gradient analysis of the pediatric patient with AML (Figure 4.4), only cells 
belonging to Leiden communities with blast phenotype were retained and the singular value 
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decomposition of the remaining rows of u was calculated. Cells were then ordered by their value 
of the second left-singular vector. Antibody counts and genotype fractions along the gradient 
were averaged with a moving window of 200 cells. Similarly, the average position of the cells in 
the two-dimensional UMAP embedding was estimated by smoothing x and y coordinates with a 
moving window of the same length. A 3rd-order spline was placed through the smoothed cell 
position to indicate the orientation of the gradient in the UMAP embedding. 
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